Announcements

Approximately 70–80% of patients with late-stage breast cancer will develop bone metastasis. This condition is currently considered incurable, and the life expectancy of these patients is around 2–3 years following diagnosis of bone involvement. Currently, we do not know which tumors are likely to progress to bone metastasis. Therefore, patients do not receive treatment until the metastasis is established and often quite large. There is a need to identify biomarkers that can be used to identify high-risk patients, enabling early intervention which could facilitate better outcomes.

When tumors arrive in bone, they become home to a metastatic niche which is made up of the endosteal niche (osteoblasts and hematopoietic stem cells) and the peri-vascular niche. Once in the niche, tumor cells can remain dormant for many years before being activated to form overt metastasis. Activation of dormant tumor cells is believed to be driven by factors that lead to the expansion of the metastatic niche, activation of cancer stem cells and/or suppression of immune regulatory mechanisms. Once tumors start to grow, tumor cells secrete factors such as PTHrP and TNF which stimulate activity of osteoclasts. Increased osteoclast activity leads to an increase in bone resorption resulting in osteolytic lesions and the release of bone-bound factors including TGFB which further increase tumor growth. This process is known as the vicious cycle of bone metastasis. Our current understanding of the processes that regulate tumor dormancy is still in its infancy. This, coupled with the complexity of tumor cell–bone cell interactions that take place during tumor growth in bone and the unique, hypoxic, immune-suppressed environment found in bone has hampered the development of more effective treatments for patients with this condition.

At the current seminar, we will highlight some of the exciting, novel work that is currently being carried out by bone metastasis experts to address pertinent gaps in our knowledge. We will investigate how miRNAs are being used to develop biomarkers for predicting the future recurrence of breast cancers in bone. Subsequently, we will explore detailed intra-vital imaging methodologies that are being used to track tumor cells as they move into the bone and lodge in the metastatic niche. We will then investigate the role of IL-1B signaling in the regulation of tumor cell dormancy before looking at new ways to improve the efficacy of immunotherapies for treating breast cancer bone metastasis.

Date: 28 June 2023 at 2:00 p.m. CEST | 8:00 a.m. EST | 8:00 p.m. CST Asia
Webinar ID: 813 4269 9012

Register now for free!

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? You are still encouraged to register, and we will let you know when the recording is available to watch.

Webinar Chair and Keynote Speakers:

• Prof. Dr. Penelope Dawn Ottewell, Department of Oncology and Metabolism, University of Sheffield, UK;
• Prof. Dr. Philippe Clézardin, INSERM, Research Unit UMR_S1033, LyOS, Faculty of Medicine Lyon-Est, France;
• Dr. Michelle McDonald, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia;
• Dr. Rachelle Whitney Johnson, Program in Cancer Biology, Vanderbilt University, USA.

Relevant Special Issue:
“Bone Metastasis in Breast Cancer”
Guest Editor: Prof. Dr. Penelope Dawn Ottewell

Submission Deadline: 1 August 2023

MDPI will be attending the 64th Annual Spring Meeting of the Japanese Society of Clinical Cytology, which will be held from 9 to 11 June 2023 in Nagoya, Japan, at the Nagoya Congress Center.

The conference is the official annual meeting of the Japanese Society of Clinical Cytology (JSCC), which is an academic organization consisting of physicians specializing in cytology and cytotechnologists who perform cytology for the purposes of cancer diagnosis and screening. Physicians specializing in cytology that belong to the society include gynecologists, surgeons, internists, and pathologists as well as cytotechnologists.

In light of current trends, the theme of this annual meeting is “Be fascinated with the mastery of cytology!—Mastering the art and passing it on to the next generations”. Cytology is deeply related to cervical cancer screening in Japan. Raising the screening rate, improving and adhering to the screening management guidelines, including colposcopy, and increasing the vaccination rate are important issues for the eradication of cervical cancer. These preventive strategies for cervical cancer will be propagated in this meeting.

The following MDPI journals will be represented:

• Cells;
• Cancers;
• Diagnostics;
• Medicina;
• Medical Sciences.

Please do not hesitate to reach out (cells@mdpi.com) if you plan on attending this conference. Our delegates look forward to meeting you in person and answering any questions that you might have.

For more information about the conference, please visit the following website: https://www.c-linkage.co.jp/jscc2023/index.html.

We are pleased to announce the winners of the Cancers 2021 Best Paper Award. All papers published in 2021 in Cancers (ISSN: 2072-6694) were considered for the award. After a thorough evaluation of the originality and significance of the papers, citations, and downloads, four winners were selected. The winners will receive CHF 500, a certificate, and a chance to publish a paper free of charge after peer review in Cancers before the end of 30 December 2023.

Winning Reviews:

“PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer”
by Alessandro Rizzo, Angela Dalia Ricci and Giovanni Brandi
Cancers 2021, 13(3), 558; https://doi.org/10.3390/cancers13030558
Available online: https://www.mdpi.com/2072-6694/13/3/558

“STING Agonists as Cancer Therapeutics”
by Afsaneh Amouzegar, Manoj Chelvanambi, Jessica N. Filderman, Walter J. Storkus and Jason J. Luke
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
Available online: https://www.mdpi.com/2072-6694/13/11/2695

Winning Articles:

“LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia”
by Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. González-Rodríguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto and Segundo Gonzalez
Cancers 2021, 13(9), 2112; https://doi.org/10.3390/cancers13092112
Available online: https://www.mdpi.com/2072-6694/13/9/2112

“The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab”
by Matteo Bauckneht, Carlo Genova, Giovanni Rossi, Erika Rijavec, Maria Giovanna Dal Bello, Giulia Ferrarazzo, Marco Tagliamento, Maria Isabella Donegani, Federica Biello, Silvia Chiola et al.
Cancers 2021, 13(13), 3117; https://doi.org/10.3390/cancers13133117
Available online: https://www.mdpi.com/2072-6694/13/13/3117

Please join us in congratulating the winners of the Cancers 2021 Best Paper Award. We would also like to take this opportunity to thank all of the authors who contributed to Cancers for their continued support.

Conference: 19^th Annual International Conference of the Metabolomics Society

Date: 18–22 June 2023

Place: Niagara Falls Convention Centre, 6815 Stanley Avenue, Niagara Falls, Ontario, Canada L2G 3Y9

Booth: #T12

MDPI will be attending the 19^th Annual International Conference of the Metabolomics Society, which will be held from 18 to 22 June 2023 in downtown Niagara Falls, Canada, at the Niagara Falls Convention Centre.

The conference is the official annual meeting of the Metabolomics Society, and the largest metabolomics meeting worldwide. It will cover the major scientific themes of: technology advances; computational metabolomics, statistics, and bioinformatics; metabolomics in health and disease; and metabolomics of plants, food, environment and microbes. A special theme for this conference will focus on mental health, drug addiction and medicinal cannabis. The scientific program will include plenary and keynote talks, three parallel scientific sessions, interactive poster sessions, sponsor lunches, other networking events and a specially organized parallel session to promote metabolomics research in industry. A strong line-up of both introductory and advanced workshops will take place on Sunday, 18 June, and the morning of Monday, 19 June. To complement the exciting scientific program, the conference will offer a welcome reception, vibrant early career events, a conference dinner and other engaging social activities.

The following MDPI journals will be represented:

• Metabolites;
• Agronomy;
• Antioxidants;
• Applied Biosciences;
• BioMed;
• BioMedInformatics;
• Biomolecules;
• Cancers;
• Cells;
• Children;
• CIMB;
• Diseases;
• Foods;
• Genes;
• JPM;
• Nutrients;
• Plants.

Please do not hesitate to reach out (metabolites@mdpi.com) if you plan on attending this conference. Our delegates look forward to meeting you in person and answering any questions that you might have.

For more information about the conference, please visit the following website: https://www.metabolomics2023.org/.

Conference: ATS (American Thoracic Society) Conference 2023
Date: 21–23 May 2023
Location: Washington DC, USA

MDPI will be attending ATS 2023 as an exhibitor; we welcome researchers from different backgrounds to visit and share their latest ideas with us.

This conference has been organized by the American Thoracic Society, and it will showcase the latest advances and discoveries in respiratory science, patient care and global respiratory health. At the conference, specialists will share and discuss the latest research and its applications to clinical, basic, and translational science in pulmonary, critical care, and sleep medicine.

The following MDPI journals will be represented:

• JCM;
• Medicina;
• Clinics and Practice;
• JPM;
• Cancers;
• Medicines;
• Healthcare;
• Metabolites;
• Children;
• Brain Sciences.

If you are planning to attend this conference, please do not hesitate to talk with us online. Our delegates look forward to meeting you in person at booth #2606, and answering any questions that you may have. For more information about the conference, please visit the following website: https://conference.thoracic.org/.

May is designated as “Bladder Cancer Awareness Month”, with various global activities that highlight and increase awareness of bladder cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of bladder cancer, published in Cancers (ISSN: 2072-6694).

We hope this announcement will provide useful information for this field.

“Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review”
by Biagio Barone, Armando Calogero, Luca Scafuri, Matteo Ferro, Giuseppe Lucarelli, Erika Di Zazzo, Enrico Sicignano, Alfonso Falcone, Lorenzo Romano, Luigi De Luca et al.
Cancers 2022, 14(10), 2545; https://doi.org/10.3390/cancers14102545

“Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis”
by Francesco Del Giudice, Rocco Simone Flammia, Benjamin I. Chung, Marco Moschini, Benjamin Pradere, Andrea Mari, Francesco Soria, Simone Albisinni, Wojciech Krajewski, Tomasz Szydełko et al.
Cancers 2022, 14(4), 887; https://doi.org/10.3390/cancers14040887

“Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy”
by Jianya Huan, Petros Grivas, Jasmine Birch and Donna E. Hansel
Cancers 2022, 14(6),1555; https://doi.org/10.3390/cancers14061555

“Long Noncoding RNA LINC02470 Sponges MicroRNA-143-3p and Enhances SMAD3-Mediated Epithelial-to-Mesenchymal Transition to Promote the Aggressive Properties of Bladder Cancer”
by Cheng-Shuo Huang, Chen-Hua Tsai, Cheng-Ping Yu, Ying-Si Wu, Ming-Fong Yee, Jar-Yi Ho and Dah-Shyong Yu
Cancers 2022, 14(4), 968; https://doi.org/10.3390/cancers14040968

“BCG in Bladder Cancer Immunotherapy”
by Song Jiang and Gil Redelman-Sidi
Cancers 2022, 14(13), 3073; https://doi.org/10.3390/cancers14133073

“The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy”
by Gad Singer, Venkat M. Ramakrishnan, Uwe Rogel, Andreas Schötzau, Daniel Disteldorf, Philipp Maletzki, Jean-Pascal Adank, Marc Hofmann, Tilo Niemann, Sylvia Stadlmann et al.
Cancers 2022, 14(3), 618; https://doi.org/10.3390/cancers14030618

“Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer”
by Stephanie N. Shishido, Salmaan Sayeed, George Courcoubetis, Hooman Djaladat, Gus Miranda, Kenneth J. Pienta, Jorge Nieva, Donna E. Hansel, Mihir Desai, Inderbir S. Gill et al.
Cancers 2022, 14(3), 758; https://doi.org/10.3390/cancers14030758

“Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy”
by Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, Gabriele Sorce, Francesco Chierigo, Andrea Panunzio, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti et al.
Cancers 2022, 14(5), 1222; https://doi.org/10.3390/cancers14051222

“Advances in Diagnosis and Therapy for Bladder Cancer”
by Xinzi Hu, Guangzhi Li and Song Wu
Cancers 2022, 14(13), 3181; https://doi.org/10.3390/cancers14133181

“The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk?”
by Achille Aveta, Crescenzo Cacciapuoti, Biagio Barone, Erika Di Zazzo, Francesco Del Giudice, Martina Maggi, Matteo Ferro, Daniela Terracciano, Gian Maria Busetto, Giuseppe Lucarelli et al.
Cancers 2022, 14(19), 4775; https://doi.org/10.3390/cancers14194775

“From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)”
by Susanne Deininger, Peter Törzsök, Michael Mitterberger, Maximilian Pallauf, David Oswald, Christian Deininger and Lukas Lusuardi
Cancers 2022, 14(3), 694; https://doi.org/10.3390/cancers14030694

“Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis”
by Julia Jacyna, Marta Kordalewska, Małgorzata Artymowicz, Marcin Markuszewski, Marcin Matuszewski and Michał J. Markuszewski
Cancers 2022, 14(5), 1210; https://doi.org/10.3390/cancers14051210

“Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review”
by Gottfrid Sjödahl, Johan Abrahamsson, Carina Bernardo, Pontus Eriksson, Mattias Höglund and Fredrik Liedberg
Cancers 2022, 14(7), 1692; https://doi.org/10.3390/cancers14071692

The list of relevant papers can be seen below:

“Diverse Roles and Targets of miRNA in the Pathogenesis of Testicular Germ Cell Tumour”
by Mrinal K.Das, Øyvind P. Haugen and Trine B. Haugen
Cancers 2022, 14(5), 1190; https://doi.org/10.3390/cancers14051190
Available online: https://www.mdpi.com/2072-6694/14/5/1190

“The Polymorphisms of Genes Encoding Catalytic Antioxidant Proteins Modulate the Susceptibility and Progression of Testicular Germ Cell Tumor”
by Uros Bumbasirevic, Nebojsa Bojanic, Marija Pljesa-Ercegovac, Marko Zivkovic, Tatjana Djukic, Milica Zekovic, Bogomir Milojevic, Boris Kajmakovic, Aleksandar Janicic, Tatjana Simic et al.
Cancers 2022, 14(4), 1068; https://doi.org/10.3390/cancers14041068
Available online: https://www.mdpi.com/2072-6694/14/4/1068

“Testicular Germ Cell Tumours and Proprotein Convertases”
by Aitziber Velado-Eguskiza, Laura Gomez-Santos, Iker Badiola, Francisco José Sáez and Edurne Alonso
Cancers 2022, 14(7), 1633; https://doi.org/10.3390/cancers14071633
Available online: https://www.mdpi.com/2072-6694/14/7/1633

“Transcriptional CDK Inhibitors as Potential Treatment Option for Testicular Germ Cell Tumors”
by Kai Funke, Robert Düster, Prince De-Graft Wilson, Lena Arévalo, Matthias Geyer and Hubert Schorle
Cancers 2022, 14(7), 1690; https://doi.org/10.3390/cancers14071690
Available online: https://www.mdpi.com/2072-6694/14/7/1690

“Comprehensive Analysis Identifies Ameloblastin-Related Competitive Endogenous RNA as a Prognostic Biomarker for Testicular Germ Cell Tumour”
by Tianxiang Geng, Catherine Anne Heyward, Xi Chen, Mengxue Zheng, Yang Yang and Janne Elin Reseland
Cancers 2022, 14(8), 1870; https://doi.org/10.3390/cancers14081870
Available online: https://www.mdpi.com/2072-6694/14/8/1870

“Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy”
by Rodrigo González-Barrios, Nicolás Alcaraz, Michel Montalvo-Casimiro, Alejandra Cervera, Cristian Arriaga-Canon, Paulina Munguia-Garza, Diego Hinojosa-Ugarte, Nora Sobrevilla-Moreno, Karla Torres-Arciga, Julia Mendoza-Perez et al.
Cancers 2022, 14(9), 2065; https://doi.org/10.3390/cancers14092065
Available online: https://www.mdpi.com/2072-6694/14/9/2065

“Imaging of Pediatric Testicular and Para-Testicular Tumors: A Pictural Review”
by Anne-Laure Hermann, Aurore L’Herminé-Coulomb, Sabine Irtan, Georges Audry, Liesbeth Cardoen, Hervé J. Brisse, Saskia Vande Perre and Hubert Ducou Le Pointe
Cancers 2022, 14(13), 3180; https://doi.org/10.3390/cancers14133180
Available online: https://www.mdpi.com/2072-6694/14/13/3180

“Testicular Germ Cell Tumours—The Role of Conventional Ultrasound”
by Jane Belfield and Charlotte Findlay-Line
Cancers 2022, 14(16), 3882; https://doi.org/10.3390/cancers14163882
Available online: https://www.mdpi.com/2072-6694/14/16/3882

“Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates—A Comprehensive Statistical Analysis”
by Klaus-Peter Dieckmann, Hendrik Isbarn, Francesca Grobelny, Cansu Dumlupinar, Julia Utschig, Christian Wülfing, Uwe Pichlmeier and Gazanfer Belge
Cancers 2022, 14(21), 5447; https://doi.org/10.3390/cancers14215447
Available online: https://www.mdpi.com/2072-6694/14/21/5447

“An Overview of the Role of Multiparametric MRI in the Investigation of Testicular Tumors”
by Athina C. Tsili, Nikolaos Sofikitis, Ourania Pappa, Christina K. Bougia and Maria I. Argyropoulou
Cancers 2022, 14(16), 3912; https://doi.org/10.3390/cancers14163912
Available online: https://www.mdpi.com/2072-6694/14/16/3912

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office
Email: cancers@mdpi.com

April is designated as “Esophageal Cancer Awareness Month”, with various global activities that highlight and increase awareness of esophageal cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of esophageal cancer, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Immunotherapy for Esophageal Cancer: State-of-the Art in 2021”
by Hugo Teixeira Farinha, Antonia Digklia, Dimitrios Schizas, Nicolas Demartines, Markus Schäfer and Styliani Mantziari
Cancers 2022, 14(3), 554; https://doi.org/10.3390/cancers14030554
Available online: https://www.mdpi.com/2072-6694/14/3/554

“Intelligent Identification of Early Esophageal Cancer by Band-Selective Hyperspectral Imaging”
by Tsung-Jung Tsai, Arvind Mukundan, Yu-Sheng Chi, Yu-Ming Tsao, Yao-Kuang Wang, Tsung-Hsien Chen, I-Chen Wu, Chien-Wei Huang and Hsiang-Chen Wang
Cancers 2022, 14(17), 4292; https://doi.org/10.3390/cancers14174292
Available online: https://www.mdpi.com/2072-6694/14/17/4292

“The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer”
by Xin Wang, Nicolas L. Palaskas, Brian P. Hobbs, Jun-ichi Abe, Kevin T. Nead, Syed Wamique Yusuf, Joerg Hermann, Anita Deswal and Steven H. Lin
Cancers 2022, 14(5), 1304; https://doi.org/10.3390/cancers14051304
Available online: https://www.mdpi.com/2072-6694/14/5/1304

“cT1N0M0 Esophageal Squamous Cell Carcinoma Invades the Muscularis Mucosa or Submucosa: Comparison of the Results of Endoscopic Submucosal Dissection and Esophagectomy”
by Ching-Ya Wang, Bo-Huan Chen, Cheng-Han Lee, Puo-Hsien Le, Yung-Kuan Tsou and Cheng-Hui Lin
Cancers 2022, 14(2), 424; https://doi.org/10.3390/cancers14020424
Available online: https://www.mdpi.com/2072-6694/14/2/424

“The KEAP1-NRF2 System and Esophageal Cancer”
by Wataru Hirose, Hiroyuki Oshikiri, Keiko Taguchi and Masayuki Yamamoto
Cancers 2022, 14(19), 4702; https://doi.org/10.3390/cancers14194702
Available online: https://www.mdpi.com/2072-6694/14/19/4702

“Endoscopic Management for Post-Surgical Complications after Resection of Esophageal Cancer”
by Dörte Wichmann, Stefano Fusco, Christoph R. Werner, Sabrina Voesch, Benedikt Duckworth-Mothes, Ulrich Schweizer, Dietmar Stüker, Alfred Königsrainer, Karolin Thiel and Markus Quante
Cancers 2022, 14(4), 980; https://doi.org/10.3390/cancers14040980
Available online: https://www.mdpi.com/2072-6694/14/4/980

“Artificial Intelligence in the Management of Barrett’s Esophagus and Early Esophageal Adenocarcinoma”
by Franz Ludwig Dumoulin, Fabian Dario Rodriguez-Monaco, Alanna Ebigbo and Ingo Steinbrück
Cancers 2022, 14(8), 1918; https://doi.org/10.3390/cancers14081918
Available online: https://www.mdpi.com/2072-6694/14/8/1918

“Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma”
by William Jiang, Jelske M. de Jong, Richard van Hillegersberg and Matthew Read
Cancers 2022, 14(4), 996; https://doi.org/10.3390/cancers14040996
Available online: https://www.mdpi.com/2072-6694/14/4/996

“The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer”
by Cameron C. J. Lang, Megan Lloyd, Said Alyacoubi, Saqib Rahman, Oliver Pickering, Tim Underwood and Stella P. Breininger
Cancers 2022, 14(5), 1171; https://doi.org/10.3390/cancers14051171
Available online: https://www.mdpi.com/2072-6694/14/5/1171

“Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas”
by Christoph Treese, Jessica Werchan, Moritz von Winterfeld, Erika Berg, Michael Hummel, Lena Timm, Beate Rau, Ole Daberkow, Wolfgang Walther, Severin Daum et al.
Cancers 2022, 14(7), 1773; https://doi.org/10.3390/cancers14071773
Available online: https://www.mdpi.com/2072-6694/14/7/1773

“Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study”
by Xing Gao, Ping-Chung Tsai, Kai-Hao Chuang, Chu-Pin Pai, Po-Kuei Hsu, Shau-Hsuan Li, Hung-I Lu, Joseph Jan-Baptist van Lanschot and Yin-Kai Chao
Cancers 2022, 14(11), 2610; https://doi.org/10.3390/cancers14112610
Available online: https://www.mdpi.com/2072-6694/14/11/2610

“Management of Superficial Esophageal Squamous Cell Carcinoma and Early Gastric Cancer following Non-Curative Endoscopic Resection”
by Waku Hatta, Tomoyuki Koike, Kaname Uno, Naoki Asano and Atsushi Masamune
Cancers 2022, 14(15), 3757; https://doi.org/10.3390/cancers14153757
Available online: https://www.mdpi.com/2072-6694/14/15/3757

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office
Email: cancers@mdpi.com

Conference: 29th Congress of the European Association for Cancer Research
Date: 12–15 June 2023
Place: Torino, Italy

MDPI will be attending the 29th Congress of the European Association for Cancer Research, held in Torino, Italy, from 12 to 15 June 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of cancer research over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest ideas with us.

The following MDPI journals will be represented:

• Cells;
• Cancers;
• Children;
• CIMB;
• Current Oncology;
• Diagnostics;
• Geriatrics;
• Healthcare;
• JCM;
• Medical Sciences.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.eacr2023.org/.

Conference: The 112th Annual Meeting of the Japanese Society of Pathology
Date: 13–15 April 2023
Place: Shimonoseki, Japan

MDPI will be attending the 112th Annual Meeting of the Japanese Society of Pathology as an exhibitor. This meeting will be held in Shimonoseki, Japan, from 13 to 15 April 2023. This conference is held every year, and the theme of the 112th edition is “Doors to Overcoming Intractable Diseases: Potential of Pathology and Pathological Diagnostics”. The aim of this meeting is to provide an opportunity for all the members who chose the path of pathology to engage in hot discussions and introduce new perspectives to pathology and diagnostic pathology.

The following MDPI journals will be represented:

• Cancers;
• Diagnostics;
• JPM;
• Pathogens;
• CIMB;
• Pathophysiology.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://site2.convention.co.jp/112jsp/english/.

We are delighted to announce one of the winners of the Cancers 2022 Best Ph.D. Thesis Award— Dr. Adria Cañellas Socias, from the University of Barcelona, Spain, for his thesis entitled “Metastatic Recurrence in Colorectal Cancer Arises from Residual EMP1+ Cells”.

We have received a large number of excellent essays from Ph.D. students and postdocs. We would like to thank the award committee for their excellent work in the hard task of selecting winners from such excellent candidates, as well as everyone who participated in this award and helped make it a huge success!

The winners will receive CHF 800, a certificate, and a chance to publish a paper free of charge after peer review in Cancers (ISSN: 2072-6694) before the end of 2023.

We are delighted to announce one of the winners of the Cancers 2022 Best Ph.D. Thesis Award—Dr. João Pedro da Silva Machado Lobo, from the University of Porto, Portugal, for his thesis entitled “Uncovering Novel Prognostic and Predictive Epigenetic Biomarkers in Malignant Testicular Germ Cell Tumors”.

We have received a large number of excellent essays from Ph.D. students and postdocs. We would like to thank the award committee for their excellent work in the hard task of selecting winners from such excellent candidates, as well as everyone who participated in this award and helped make it a huge success!

The winners will receive CHF 800, a certificate, and a chance to publish a paper free of charge after peer review in Cancers (ISSN: 2072-6694) before the end of 2023.

MDPI will be attending the Chinese Academic Conference on Tumor Biomarker, held in Shanghai, China, from 7 to 9 April 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of tumor markers over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest inspirations with us.

The following MDPI journals will be represented:

• Biomedicines;
• Cancers;
• Cells;
• Diagnostics;
• Current Oncology;
• JPM;
• JCM;
• Onco;
• CIMB;
• BioMedInformatics.

If you plan on attending this conference, feel free to stop by our booth, #B155. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please follow the link below: https://biomarker2022.sciconf.cn/cn/web/index/13496.

We are delighted to announce the winners of the Cancers 2022 Young Investigator Award. Additionally, we want to thank the award committee for their excellent work in the hard task of selecting a winner from such excellent candidates, as well as everyone who participated in this award and helped ensure it was a huge success!

A special congratulations to the winners—Dr. Ashleigh Poh and Dr. Miranda Fidler-Benaoudia.

Dr. Ashleigh Poh is an early career post-doctoral research fellow at the Olivia Newton-John Cancer Research Institute, Australia. She received her Ph.D. in 2017. Her work focuses on therapeutic approaches to re-invigorate anti-tumor immunity by reprogramming immunosuppressive myeloid cells towards an immune-stimulatory endotype. Dr. Ashleigh Poh’s research was the first to identify a tumor cell-extrinsic role for the myeloid-specific kinase HCK in solid cancers by enhancing the polarization of immunosuppressive ‘alternatively activated’ macrophages. These discoveries have leveraged major industry partnerships to develop small molecule HCK inhibitors for clinical use. Dr. Ashleigh Poh independently secured more than 1.5 million dollars in competitive funding as a principal investigator. Her ability to generate high-quality research is also evidenced by her winning 20 awards and delivering 30 invited presentations. Dr. Ashleigh Poh’s expertise in tumor immunology has resulted in 23 publications (13 as first/senior author) in prestigious journals including Cell, Cancer Cell and Science Advances.

Dr. Miranda Fidler-Benaoudia is a cancer epidemiologist/research scientist at Alberta Health Services, Canada, and is an Adjunct Assistant Professor at the University of Calgary, Canada. Her research focuses on understanding the magnitude of the late effects among survivors of childhood, adolescent and young adult cancer and developing tertiary prevention interventions to mitigate cancer- and treatment-related sequalae. She is interested in sub-populations, such as indigenous peoples, and she comprehensively undertakes research to describe cancer indicators nationally, regionally and globally. Prior to her current positions, she received her Ph.D. at the University of Birmingham, UK, in 2015, and completed a postdoctoral fellowship at the International Agency for Research on Cancer, France, from 2015 to 2018. She has significantly contributed to the field of oncology as a young investigator, with 44 peer-reviewed publications, 4 invited oral presentations and 34 oral/poster presentations, as well as numerous memberships on editorial boards and national committees. Finally, she has received over 2.1 million dollars in funding as the nominated principal applicant since commencing her independent research four years ago.

Please join us in congratulating Dr. Ashleigh Poh and Dr. Miranda Fidler-Benaoudia for their outstanding achievements.

As the awardees, they will receive an honorarium of CHF 2000, an electronic certificate, an offer to publish a paper free of charge before the end of 2023 in Cancers (ISSN: 2072-6694) after peer review and an engraved plaque.

We thank all those who nominated a candidate from various fields of study for their participation and all the Award Committee members for their evaluation of the many excellent nominees.

1. “The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis”
   by Deniz Can Guven, Taha Koray Sahin, Enes Erul, Saadettin Kilickap, Thilo Gambichler and Sercan Aksoy
   Cancers 2022, 14(11), 2675; https://doi.org/10.3390/cancers14112675
   Available online: https://www.mdpi.com/2072-6694/14/11/2675

2. “Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy”
   by Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, Kazuki Maesaka, Takayuki Matsumae, Yoshiyuki Sawai, Yasuharu Imai, Kazuyoshi Ohkawa, Masanori Miyazaki, Satoshi Tanaka et al.
   Cancers 2022, 14(4), 883; https://doi.org/10.3390/cancers14040883
   Available online: https://www.mdpi.com/2072-6694/14/4/883

3. “HPRT1 Promotes Chemoresistance in Oral Squamous Cell Carcinoma via Activating MMP1/PI3K/Akt Signaling Pathway”
   by Tong Wu, Zan Jiao, Yixuan Li, Xuan Su, Fan Yao, Jin Peng, Weichao Chen and Ankui Yang
   Cancers 2022, 14(4), 855; https://doi.org/10.3390/cancers14040855
   Available online: https://www.mdpi.com/2072-6694/14/4/855

4. “Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy”
   by Pauline Gilson, Jean-Louis Merlin and Alexandre Harlé
   Cancers 2022, 14(6), 1384; https://doi.org/10.3390/cancers14061384
   Available online: https://www.mdpi.com/2072-6694/14/6/1384

5. “Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer”
   by Camille Domergue, Elodie Martin, Camille Lemarié, Pascal Jézéquel, Jean-Sebastien Frenel, Paule Augereau, Mario Campone and Anne Patsouris
   Cancers 2022, 14(10), 2509; https://doi.org/10.3390/cancers14102509
   Available online: https://www.mdpi.com/2072-6694/14/10/2509

6. “Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs”
   by Elena Tomeva, Olivier J. Switzeny, Clemens Heitzinger, Berit Hippe and Alexander G. Haslberger
   Cancers 2022, 14(2), 462; https://doi.org/10.3390/cancers14020462
   Available online: https://www.mdpi.com/2072-6694/14/2/462

7. “Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma”
   by Mariella Faccia, Matteo Garcovich, Maria Elena Ainora, Laura Riccardi, Maurizio Pompili, Antonio Gasbarrini and Maria Assunta Zocco
   Cancers 2022, 14(3), 481; https://doi.org/10.3390/cancers14030481
   Available online: https://www.mdpi.com/2072-6694/14/3/481

8. “Long Noncoding RNA LINC02470 Sponges MicroRNA-143-3p and Enhances SMAD3-Mediated Epithelial-to-Mesenchymal Transition to Promote the Aggressive Properties of Bladder Cancer”
   by Cheng-Shuo Huang, Chen-Hua Tsai, Cheng-Ping Yu, Ying-Si Wu, Ming-Fong Yee, Jar-Yi Ho and Dah-Shyong Yu
   Cancers 2022, 14(4), 968; https://doi.org/10.3390/cancers14040968
   Available online: https://www.mdpi.com/2072-6694/14/4/968

9. “Imaging Kv1.3 Expressing Memory T Cells as a Marker of Immunotherapy Response”
   by Julian L. Goggi, Shivashankar Khanapur, Boominathan Ramasamy, Siddesh V. Hartimath, Tang Jun Rong, Peter Cheng, Yun Xuan Tan, Xin Yi Yeo, Sangyong Jung, Stephanie Shee Min Goay et al.
   Cancers 2022, 14(5), 1217; https://doi.org/10.3390/cancers14051217
   Available online: https://www.mdpi.com/2072-6694/14/5/1217

10. “Automatically Extracted Machine Learning Features from Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT)”
    by Matteo Renzulli, Margherita Mottola, Francesca Coppola, Maria Adriana Cocozza, Silvia Malavasi, Arrigo Cattabriga, Giulio Vara, Matteo Ravaioli, Matteo Cescon, Francesco Vasuri et al.
    Cancers 2022, 14(7), 1816; https://doi.org/10.3390/cancers14071816
    Available online: https://www.mdpi.com/2072-6694/14/7/1816

1. “Environmental Risk Factors for Childhood Acute Lymphoblastic Leukemia: An Umbrella Review”
   by Felix M. Onyije, Ann Olsson, Dan Baaken, Friederike Erdmann, Martin Stanulla, Daniel Wollschläger and Joachim Schüz
   Cancers 2022, 14(2), 382; https://doi.org/10.3390/cancers14020382
   Available online: https://www.mdpi.com/2072-6694/14/2/382

2. “Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth”
   by Rameswari Chilamakuri and Saurabh Agarwal
   Cancers 2022, 14(4), 1067; https://doi.org/10.3390/cancers14041067
   Available online: https://www.mdpi.com/2072-6694/14/4/1067

3. “Gastrointestinal Adenocarcinoma Incidence and Survival Trends in South Australia, 1990–2017”
   by Dominique Schell, Shahid Ullah, Mark E. Brooke-Smith, Paul Hollington, Marina Yeow, Christos S. Karapetis, David I. Watson, Stephen J. Pandol, Claire T. Roberts and Savio G. Barreto
   Cancers 2022, 14(2), 275; https://doi.org/10.3390/cancers14020275
   Available online: https://www.mdpi.com/2072-6694/14/2/275

4. “Management of Nutritional Needs in Pediatric Oncology: A Consensus Statement”
   by Francesco Fabozzi, Chiara Maria Trovato, Antonella Diamanti, Angela Mastronuzzi, Marco Zecca, Serena Ilaria Tripodi, Riccardo Masetti, Davide Leardini, Edoardo Muratore, Veronica Barat et al.
   Cancers 2022, 14(14), 3378; https://doi.org/10.3390/cancers14143378
   Available online: https://www.mdpi.com/2072-6694/14/14/3378

5. “NanoString Digital Molecular Profiling of Protein and microRNA in Rhabdomyosarcoma”
   by Atif A. Ahmed, Midhat S. Farooqi, Sultan S. Habeebu, Elizabeth Gonzalez, Terrie G. Flatt, Ashley L. Wilson and Frederic G. Barr
   Cancers 2022, 14(3), 522; https://doi.org/10.3390/cancers14030522
   Available online: https://www.mdpi.com/2072-6694/14/3/522

6. “Cannabinol Inhibits Cellular Proliferation, Invasion, and Angiogenesis of Neuroblastoma via Novel miR-34a/tRiMetF31/PFKFB3 Axis”
   by Bo Wang, Dongping Li, Viktoriia Cherkasova, Marta Gerasymchuk, Aru Narendran, Igor Kovalchuk and Olga Kovalchuk
   Cancers 2022, 14(8), 1908; https://doi.org/10.3390/cancers14081908
   Available online: https://www.mdpi.com/2072-6694/14/8/1908

7. “New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma”
   by Francia Y. Fang, Jared S. Rosenblum, Winson S. Ho and John D. Heiss
   Cancers 2022, 14(9), 2285; https://doi.org/10.3390/cancers14092285
   Available online: https://www.mdpi.com/2072-6694/14/9/2285

8. “Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins”
   by Charlie Buchou, Karine Laud-Duval, Wietske van der Ent, Sandrine Grossetête, Sakina Zaidi, Géraldine Gentric, Maxime Corbé, Kévin Müller, Elaine Del Nery, Didier Surdez et al.
   Cancers 2022, 14(9), 2327; https://doi.org/10.3390/cancers14092327
   Available online: https://www.mdpi.com/2072-6694/14/9/2327

9. “Computer-Based Cognitive Training in Children with Primary Brain Tumours: A Systematic Review”
   by Francesco Sciancalepore, Leonardo Tariciotti, Giulia Remoli, Danilo Menegatti, Andrea Carai, Giuseppe Petruzzellis, Kiersten P. Miller, Francesco Delli Priscoli, Alessandro Giuseppi, Roberto Premuselli et al.
   Cancers 2022, 14(16), 3879; https://doi.org/10.3390/cancers14163879
   Available online: https://www.mdpi.com/2072-6694/14/16/3879

10. “Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol”
    by Ewa Koscielniak, Bernd Blank, Christian Vokuhl, Bernarda Kazanowska, Ruth Ladenstein, Felix Niggli, Gustaf Ljungman, Rupert Handgretinger, Guido Seitz, Jörg Fuchs et al.
    Cancers 2022, 14(4), 899; https://doi.org/10.3390/cancers14040899
    Available online: https://www.mdpi.com/2072-6694/14/4/899

As a leading open access publisher, MDPI provides scholars with a high-quality and rich academic exchange platform by continuously expanding into new and exciting research areas.

In December 2022, MDPI launched five new journals, covering multiple subjects such as life sciences, biology, medicine and pharmacology, social sciences and humanities. These new journals are being edited by established scholars across the world.

If you are interested in creating more open access journals with us to publish cutting-edge research, please send your journal proposal application to newjournal-committee@mdpi.com.

1. “Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets”
by Ralf-Peter Czekay, Dong-Joo Cheon, Rohan Samarakoon, Stacie M. Kutz and Paul J. Higgins
Cancers 2022, 14(5), 1231; https://doi.org/10.3390/cancers14051231
Available online: https://www.mdpi.com/2072-6694/14/5/1231

2. “AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis”
by Marie-Anne Goyette and Jean-François Côté
Cancers 2022, 14(3), 466; https://doi.org/10.3390/cancers14030466
Available online: https://www.mdpi.com/2072-6694/14/3/466

3. “Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy”
by Leah Davis, Matthias Recktenwald, Evan Hutt, Schuyler Fuller, Madison Briggs, Arnav Goel and Nichole Daringer
Cancers 2022, 14(5), 1259; https://doi.org/10.3390/cancers14051259
Available online: https://www.mdpi.com/2072-6694/14/5/1259

4. “Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses”
by Maximilian Rentschler, Heidi Braumüller, Priscilla S. Briquez and Thomas Wieder
Cancers 2022, 14(6), 1364; https://doi.org/10.3390/cancers14061364
Available online: https://www.mdpi.com/2072-6694/14/6/1364

5. “Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context”
by Mannon Geindreau, Mélanie Bruchard and Frédérique Vegran
Cancers 2022, 14(10), 2446; https://doi.org/10.3390/cancers14102446
Available online: https://www.mdpi.com/2072-6694/14/10/2446

6. “STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential”
by Sarah Q. To, Rhynelle S. Dmello, Anna K. Richards, Matthias Ernst and Ashwini L. Chand
Cancers 2022, 14(2), 429; https://doi.org/10.3390/cancers14020429
Available online: https://www.mdpi.com/2072-6694/14/2/429

7.“Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy”
by Jang Hyun Park and Heung Kyu Lee
Cancers 2022, 14(5), 1176; https://doi.org/10.3390/cancers14051176
Available online: https://www.mdpi.com/2072-6694/14/5/1176

8. “Impact of Lipid Metabolism on Antitumor Immune Response”
by Nesrine Mabrouk, Baptiste Lecoeur, Ali Bettaieb, Catherine Paul and Frédérique Végran
Cancers 2022, 14(7), 1850; https://doi.org/10.3390/cancers14071850
Available online: https://www.mdpi.com/2072-6694/14/7/1850

9. “Therapeutic Potential of Naturally Occurring Small Molecules to Target the Wnt/β-Catenin Signaling Pathway in Colorectal Cancer”
by Luiz F. S. Oliveira, Danilo Predes, Helena L. Borges and Jose G. Abreu
Cancers 2022, 14(2), 403; https://doi.org/10.3390/cancers14020403
Available online: https://www.mdpi.com/2072-6694/14/2/403

10. “Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment”
by Nan Sethakorn, Erika Heninger, Cristina Sánchez-de-Diego, Adeline B. Ding, Ravi Chandra Yada, Sheena C. Kerr, David Kosoff, David J. Beebe and Joshua M. Lang
Cancers 2022, 14(3), 757; https://doi.org/10.3390/cancers14030757
Available online: https://www.mdpi.com/2072-6694/14/3/757

MDPI is pleased to announce that we now display the co-authors’ email addresses in addition to the corresponding author’s email address on the webpage of published papers, protected by Captcha. For more information about this change, please visit the journal’s instructions for authors page. 

We believe this change will facilitate academic discussions and advance our cause of open science and research. The corresponding authors are responsible for communicating with their co-authors and indicating in our system (https://susy.mdpi.com/) if co-authors would prefer for their email addresses not to be displayed.

1. “Breast Tumour Classification Using Ultrasound Elastography with Machine Learning: A Systematic Scoping Review”
by Ye-Jiao Mao, Hyo-Jung Lim, Ming Ni, Wai-Hin Yan, Duo Wai-Chi Wong and James Chung-Wai Cheung
Cancers 2022, 14(2), 367; https://doi.org/10.3390/cancers14020367
Available online: https://www.mdpi.com/2072-6694/14/2/367

2. “CT-Based Radiomics Analysis to Predict Histopathological Outcomes Following Liver Resection in Colorectal Liver Metastases”
by Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Federica De Muzio, Federica Dell’ Aversana, Carmen Cutolo, Lorenzo Faggioni, Vittorio Miele, Francesco Izzo and Antonella Petrillo
Cancers 2022, 14(7), 1648; https://doi.org/10.3390/cancers14071648
Available online: https://www.mdpi.com/2072-6694/14/7/1648

3. “Contrast MR-Based Radiomics and Machine Learning Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases: A Preliminary Study”
by Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Sergio Venanzio Setola, Federica dell’ Aversana, Alessandro Ottaiano, Antonio Avallone, Guglielmo Nasti, Francesca Grassi et al.
Cancers 2022, 14(5), 1110; https://doi.org/10.3390/cancers14051110
Available online: https://www.mdpi.com/2072-6694/14/5/1110

4. “Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers”
by Alicia Cristina Peña-Romero and Esteban Orenes-Piñero
Cancers 2022, 14(7), 1681; https://doi.org/10.3390/cancers14071681
Available online: https://www.mdpi.com/2072-6694/14/7/1681

5. “Advanced Magnetic Resonance Imaging (MRI) Techniques: Technical Principles and Applications in Nanomedicine”
by Federico Bruno, Vincenza Granata, Flavia Cobianchi Bellisari, Ferruccio Sgalambro, Emanuele Tommasino, Pierpaolo Palumbo, Francesco Arrigoni, Diletta Cozzi, Francesca Grassi, Maria Chiara Brunese et al.
Cancers 2022, 14(7), 1626; https://doi.org/10.3390/cancers14071626
Available online: https://www.mdpi.com/2072-6694/14/7/1626

6. “Radiolabeled Antibodies for Cancer Imaging and Therapy”
by Sagun Parakh, Sze Ting Lee, Hui K. Gan and Andrew M. Scott
Cancers 2022, 14(6), 1454; https://doi.org/10.3390/cancers14061454
Available online: https://www.mdpi.com/2072-6694/14/6/1454

7. “What Does PET Imaging Bring to Neuro-Oncology in 2022? A Review”
by Jules Tianyu Zhang-Yin, Antoine Girard and Marc Bertaux
Cancers 2022, 14(4), 879; https://doi.org/10.3390/cancers14040879
Available online: https://www.mdpi.com/2072-6694/14/4/879

8. “Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer”
by Maria Teresa Masucci, Michele Minopoli, Gioconda Di Carluccio, Maria Letizia Motti and Maria Vincenza Carriero
Cancers 2022, 14(3), 498; https://doi.org/10.3390/cancers14030498
Available online: https://www.mdpi.com/2072-6694/14/3/498

9. “The Practicality of the Use of Liquid Biopsy in Early Diagnosis and Treatment Monitoring of Oral Cancer in Resource-Limited Settings”
by Henry Ademola Adeola, Ibrahim O. Bello, Raphael Taiwo Aruleba, Ngiambudulu M. Francisco, Tayo Alex Adekiya, Anthonio Oladele Adefuye, Paul Chukwudi Ikwegbue and Fungai Musaigwa
Cancers 2022, 14(5), 1139; https://doi.org/10.3390/cancers14051139
Available online: https://www.mdpi.com/2072-6694/14/5/1139

10. “Effect of 5-Aminolevulinic Acid and Sodium Fluorescein on the Extent of Resection in High-Grade Gliomas and Brain Metastasis”
by Lasse Cramer Ahrens, Mathias Green Krabbenhøft, Rasmus Würgler Hansen, Nikola Mikic, Christian Bonde Pedersen, Frantz Rom Poulsen and Anders Rosendal Korshoej
Cancers 2022, 14(3), 617; https://doi.org/10.3390/cancers14030617
Available online: https://www.mdpi.com/2072-6694/14/3/617

1. “Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy”
by Jerzy Jaroszewicz, Justyna Kowalska, Małgorzata Pawłowska, Magdalena Rogalska, Dorota Zarębska-Michaluk, Marta Rorat, Beata Lorenc, Piotr Czupryna, Katarzyna Sikorska, Anna Piekarska et al.
Cancers 2022, 14(19), 4720; https://doi.org/10.3390/cancers14194720
Available online: https://www.mdpi.com/2072-6694/14/19/4720

2. “Hospital-Treated Infections and Increased Risk of Two EBV-Related Malignancies: A Nested Case-Control Study”
by Yanping Yang, Li Yin, Qianwei Liu, Jiangwei Sun, Hans-Olov Adami, Weimin Ye, Zhe Zhang and Fang Fang
Cancers 2022, 14(15), 3804; https://doi.org/10.3390/cancers14153804
Available online: https://www.mdpi.com/2072-6694/14/15/3804

3. “Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination”
by Lorenz Schubert, Maximilian Koblischke, Lisa Schneider, Edit Porpaczy, Florian Winkler, Ulrich Jaeger, Stephan Blüml, Helmuth Haslacher, Heinz Burgmann, Judith H. Aberle et al.
Cancers 2022, 14(8), 1962; https://doi.org/10.3390/cancers14081962
Available online: https://www.mdpi.com/2072-6694/14/8/1962

4. “Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis”
by Jina Kim, Hwa Kyung Byun, Tae Hyung Kim, Sun Il Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim and Jinsil Seong
Cancers 2022, 14(10), 2396; https://doi.org/10.3390/cancers14102396
Available online: https://www.mdpi.com/2072-6694/14/10/2396

5. “Distribution of HPV Subtypes in Diverse Anogenital and Oral Samples from Women and Correlation of Infections with Neoplasia of the Cervix”
by Karen Bräutigam, Stefanie Meier, Sabina Meneder, Louisa Proppe, Katharina Stroschein, Stephan Polack, Frank Köster, Achim Rody and Sascha Baum
Cancers 2022, 14(13), 3136; https://doi.org/10.3390/cancers14133136
Available online: https://www.mdpi.com/2072-6694/14/13/3136

6. “HBV preS Mutations Promote Hepatocarcinogenesis by Inducing Endoplasmic Reticulum Stress and Upregulating Inflammatory Signaling”
by Wenbin Liu, Shiliang Cai, Rui Pu, Zixiong Li, Donghong Liu, Xinyu Zhou, Jianhua Yin, Xi Chen, Liping Chen, Jianfeng Wu et al.
Cancers 2022, 14(13), 3274; https://doi.org/10.3390/cancers14133274
Available online: https://www.mdpi.com/2072-6694/14/13/3274

7. “Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis”
by Evgenii Shumilov, Lena Aperdannier, Nicole Schmidt, Christoph Szuszies, Albrecht Neesse, Petra Hoffknecht, Cyrus Khandanpour, Jan-Henrik Mikesch, Matthias Stelljes, Göran Ramin Boeckel et al.
Cancers 2022, 14(15), 3746; https://doi.org/10.3390/cancers14153746
Available online: https://www.mdpi.com/2072-6694/14/15/3746

8. “Intestinal Klebsiella pneumoniae Contributes to Pneumonia by Synthesizing Glutamine in Multiple Myeloma”
by Yihui Wang, Qin Yang, Yinghong Zhu, Xingxing Jian, Jiaojiao Guo, Jingyu Zhang, Chunmei Kuang, Xiangling Feng, Gang An, Lugui Qiu et al.
Cancers 2022, 14(17), 4188; https://doi.org/10.3390/cancers14174188
Available online: https://www.mdpi.com/2072-6694/14/17/4188

9. “Oncogenic and Stemness Signatures of the High-Risk HCMV Strains in Breast Cancer Progression”
by Ranim El Baba, Sébastien Pasquereau, Sandy Haidar Ahmad, Mona Diab-Assaf and Georges Herbein
Cancers 2022, 14(17), 4271; https://doi.org/10.3390/cancers14174271
Available online: https://www.mdpi.com/2072-6694/14/17/4271

10. “2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus”

by Pavel O. Vorobyev, Dmitry V. Kochetkov, Peter M. Chumakov, Natalia F. Zakirova, Sofia I. Zotova-Nefedorova, Konstantin V. Vasilenko, Olga N. Alekseeva, Sergey N. Kochetkov, Birke Bartosch, Anastasiya V. Lipatova et al.
Cancers 2022, 14(22), 5611; https://doi.org/10.3390/cancers14225611
Available online: https://www.mdpi.com/2072-6694/14/22/5611

1. “The Functional Role of Extracellular Matrix Proteins in Cancer”
by Nadezhda V. Popova and Manfred Jücker
Cancers 2022, 14(1), 238; https://doi.org/10.3390/cancers14010238
Available online: https://www.mdpi.com/2072-6694/14/1/238

2. “Recent Advances of Deep Learning for Computational Histopathology: Principles and Applications”
by Yawen Wu, Michael Cheng, Shuo Huang, Zongxiang Pei, Yingli Zuo, Jianxin Liu, Kai Yang, Qi Zhu, Jie Zhang, Honghai Hong et al.
Cancers 2022, 14(5), 1199; https://doi.org/10.3390/cancers14051199
Available online: https://www.mdpi.com/2072-6694/14/5/1199

3. “Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine”
by Ellen S. Smith, Eric Whitty, Byunghee Yoo, Anna Moore, Lorenzo F. Sempere and Zdravka Medarova
Cancers 2022, 14(6), 1588; https://doi.org/10.3390/cancers14061588
Available online: https://www.mdpi.com/2072-6694/14/6/1588

4. “Validation in an Independent Cohort of MiR-122, MiR-1271, and MiR-15b as Urinary Biomarkers for the Potential Early Diagnosis of Clear Cell Renal Cell Carcinoma”
by Giovanni Cochetti, Luigi Cari, Vincenza Maulà, Rosy Cagnani, Alessio Paladini, Michele Del Zingaro, Giuseppe Nocentini and Ettore Mearini
Cancers 2022, 14(5), 1112; https://doi.org/10.3390/cancers14051112
Available online: https://www.mdpi.com/2072-6694/14/5/1112

5. “A Deep Learning Model for Cervical Cancer Screening on Liquid-Based Cytology Specimens in Whole Slide Images”
by Fahdi Kanavati, Naoki Hirose, Takahiro Ishii, Ayaka Fukuda, Shin Ichihara and Masayuki Tsuneki
Cancers 2022, 14(5), 1159; https://doi.org/10.3390/cancers14051159
Available online: https://www.mdpi.com/2072-6694/14/5/1159

6. “Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases”
by Valentina Giannini, Laura Pusceddu, Arianna Defeudis, Giulia Nicoletti, Giovanni Cappello, Simone Mazzetti, Andrea Sartore-Bianchi, Salvatore Siena, Angelo Vanzulli, Francesco Rizzett et al.
Cancers 2022, 14(1), 241; https://doi.org/10.3390/cancers14010241
Available online: https://www.mdpi.com/2072-6694/14/1/241

7. “Cancer-on-a-Chip: Models for Studying Metastasis”
by Xiaojun Zhang, Mazharul Karim, Md Mahedi Hasan, Jacob Hooper, Riajul Wahab, Sourav Roy and Taslim A. Al-Hilal
Cancers 2022, 14(3), 648; https://doi.org/10.3390/cancers14030648
Available online: https://www.mdpi.com/2072-6694/14/3/648

8. “Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection”
by Faddy Kamel, Khadiga Eltarhoni, Pasha Nisar and Mikhail Soloviev
Cancers 2022, 14(8), 1889; https://doi.org/10.3390/cancers14081889
Available online: https://www.mdpi.com/2072-6694/14/8/1889

9. “Targeting Wnt/β;-Catenin Signaling by TET1/FOXO4 Inhibits Metastatic Spreading and Self-Renewal of Cancer Stem Cells in Gastric Cancer”
by Jingjing Qi, Di Cui, Qi-Nian Wu, Qi Zhao, Zhan-Hong Chen, Lianjie Li, Walter Birchmeier, Yong Yu and Ran Tao
Cancers 2022, 14(13), 3232; https://doi.org/10.3390/cancers14133232
Available online: https://www.mdpi.com/2072-6694/14/13/3232

10. “The Antitumor Effect of Caffeic Acid Phenethyl Ester by Downregulating Mucosa-Associated Lymphoid Tissue 1 via AR/p53/NF-κB Signaling in Prostate Carcinoma Cells”
by Kang-Shuo Chang, Ke-Hung Tsui, Shu-Yuan Hsu, Hsin-Ching Sung, Yu-Hsiang Lin, Chen-Pang Hou, Pei-Shan Yang, Chien-Lun Chen, Tsui-Hsia Feng and Horng-Heng Juang
Cancers 2022, 14(2), 274; https://doi.org/10.3390/cancers14020274
Available online: https://www.mdpi.com/2072-6694/14/2/274

1. “Cannabidiol (CBD) in Cancer Management”
by Kylie O’Brien
Cancers 2022, 14(4), 885; https://doi.org/10.3390/cancers14040885
Available online: https://www.mdpi.com/2072-6694/14/4/885

2. “Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells”
by Timothy Crook, Robert Leonard, Kefah Mokbel, Alastair Thompson, Michael Michell, Raymond Page, Ashok Vaid, Ravi Mehrotra, Anantbhushan Ranade, Sewanti Limaye et al.
Cancers 2022, 14(14), 3341; https://doi.org/10.3390/cancers14143341
Available online: https://www.mdpi.com/2072-6694/14/14/3341

3. “Timely Palliative Care: Personalizing the Process of Referral”
by David Hui, Yvonne Heung and Eduardo Bruera
Cancers 2022, 14(4), 1047; https://doi.org/10.3390/cancers14041047
Available online: https://www.mdpi.com/2072-6694/14/4/1047

4. “Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?”
by Saikat Mitra, Mashia Subha Lami, Avoy Ghosh, Rajib Das, Trina Ekawati Tallei, Fatimawali, Fahadul Islam, Kuldeep Dhama, M. Yasmin Begum, Afaf Aldahish et al.
Cancers 2022, 14(3), 759; https://doi.org/10.3390/cancers14030759
Available online: https://www.mdpi.com/2072-6694/14/3/759

5. “Sex Differences in the Effect of Vitamin D on Fatigue in Palliative Cancer Care—A Post Hoc Analysis of the Randomized, Controlled Trial ‘Palliative-D’”
by Caritha Klasson, Maria Helde Frankling, Anna Warnqvist, Carina Sandberg, Marie Nordström, Carina Lundh-Hagelin and Linda Björkhem-Bergman
Cancers 2022, 14(3), 746; https://doi.org/10.3390/cancers14030746
Available online: https://www.mdpi.com/2072-6694/14/3/746

6. “Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors”
by Argyro Papadopetraki, Maria Maridaki, Flora Zagouri, Meletios-Athanasios Dimopoulos, Michael Koutsilieris and Anastassios Philippou
Cancers 2022, 14(8), 1892; https://doi.org/10.3390/cancers14081892
Available online: https://www.mdpi.com/2072-6694/14/8/1892

7. “Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives”
by Cécile Torregrosa, Frédéric Chorin, Eva Ester Molina Beltran, Cindy Neuzillet and Victoire Cardot-Ruffino
Cancers 2022, 14(21), 5402; https://doi.org/10.3390/cancers14215402
Available online: https://www.mdpi.com/2072-6694/14/21/5402

8. “Sinonasal Inverted Papilloma and Squamous Cell Carcinoma: Contemporary Management and Patient Outcomes”
by Jacob G. Eide, Kevin C. Welch, Nithin D. Adappa, James N. Palmer and Charles C. L. Tong
Cancers 2022, 14(9), 2195; https://doi.org/10.3390/cancers14092195
Available online: https://www.mdpi.com/2072-6694/14/9/2195

9. “Supportive Care Needs Assessment for Cancer Survivors at a Comprehensive Cancer Center in the Middle East: Mending the Gap”
by Amal Al-Omari, Nedal Al-Rawashdeh, Rana Damsees, Khawlah Ammar, Ibrahim Alananzeh, Bayan Inserat, Dalia Al-Rimawi, Shrouq Tbayshat, Hazim Ababneh, Haneen Alishreim et al.
Cancers 2022, 14(4), 1002; https://doi.org/10.3390/cancers14041002
Available online: https://www.mdpi.com/2072-6694/14/4/1002

10. “Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer”
by Karel C. Smit, Jeroen W. G. Derksen, Geerard L. O. Beets, Eric J. Th. Belt, Maaike Berbée, Peter Paul L. O. Coene, Hester van Cruijsen, Marjan A. Davidis, Jan Willem T. Dekker, Joyce M. van Dodewaard-de Jong et al.
Cancers 2022, 14(4), 1001; https://doi.org/10.3390/cancers14041001
Available online: https://www.mdpi.com/2072-6694/14/4/1001

1. “Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis”
by Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, Silvana Acquafredda, Lucia Rinaldi, Andrea Misino, Elisabetta Sara Montagna, Valentina Ungaro, Mariagrazia Lorusso and Gennaro Palmiotti
Cancers 2022, 14(6), 1404; https://doi.org/10.3390/cancers14061404
Available online: https://www.mdpi.com/2072-6694/14/6/1404

2. “The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions”
by Tadeusz Robak, Magda Witkowska and Piotr Smolewski
Cancers 2022, 14(3), 771; https://doi.org/10.3390/cancers14030771
Available online: https://www.mdpi.com/2072-6694/14/3/771

3. “The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer”
by Irem Ozel, Inga Duerig, Maksim Domnich, Stephan Lang, Ekaterina Pylaeva and Jadwiga Jablonska
Cancers 2022, 14(3), 536; https://doi.org/10.3390/cancers14030536
Available online: https://www.mdpi.com/2072-6694/14/3/536

4. “Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study”
by Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon and Hong Jae Chon
Cancers 2022, 14(7), 1747; https://doi.org/10.3390/cancers14071747
Available online: https://www.mdpi.com/2072-6694/14/7/1747

5. “Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer”
by Ching-Hung Hsieh, Cheng-Zhe Jian, Liang-In Lin, Guan-Sian Low, Ping-Yun Ou, Chiun Hsu and Da-Liang Ou
Cancers 2022, 14(2), 294; https://doi.org/10.3390/cancers14020294
Available online: https://www.mdpi.com/2072-6694/14/2/294

6. “Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma”
by Tomoko Aoki, Naoshi Nishida and Masatoshi Kudo
Cancers 2022, 14(2), 444; https://doi.org/10.3390/cancers14020444
Available online: https://www.mdpi.com/2072-6694/14/2/444

by Biagio Barone, Armando Calogero, Luca Scafuri, Matteo Ferro, Giuseppe Lucarelli, Erika Di Zazzo, Enrico Sicignano, Alfonso Falcone, Lorenzo Romano, Luigi De Luca et al.
Cancers 2022, 14(10), 2545; https://doi.org/10.3390/cancers14102545
Available online: https://www.mdpi.com/2072-6694/14/10/2545

8. “Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine”
by Nicolas Huyghe, Elena Benidovskaya, Philippe Stevens and Marc Van den Eynde
Cancers 2022, 14(9), 2241; https://doi.org/10.3390/cancers14092241
Available online: https://www.mdpi.com/2072-6694/14/9/2241

9. “Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes”
by Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco et al.
Cancers 2022, 14(10), 2429; https://doi.org/10.3390/cancers14102429
Available online: https://www.mdpi.com/2072-6694/14/10/2429

10. “Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities”
by Carmelo Laface, Palma Fedele, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Pasquale Molinari, Michele Ammendola, Marco Lioce and Girolamo Ranieri
Cancers 2022, 14(16), 4028; https://doi.org/10.3390/cancers14164028
Available online: https://www.mdpi.com/2072-6694/14/16/4028

1. “Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence”
by Aramini Beatrice, Valentina Masciale, Giulia Grisendi, Federica Bertolini, Michela Maur, Giorgia Guaitoli, Isca Chrystel, Uliano Morandi, Franco Stella, Massimo Dominici et al.
Cancers 2022, 14(4), 976; https://doi.org/10.3390/cancers14040976
Available online: https://www.mdpi.com/2072-6694/14/4/976

2. “CTCF Expression and Dynamic Motif Accessibility Modulates Epithelial–Mesenchymal Gene Expression”
by Kelsey S. Johnson, Shaimaa Hussein, Priyanka Chakraborty, Arvind Muruganantham, Sheridan Mikhail, Giovanny Gonzalez, Shuxuan Song, Mohit Kumar Jolly, Michael J. Toneff, Mary Lauren Benton et al.
Cancers 2022, 14(1), 209; https://doi.org/10.3390/cancers14010209
Available online: https://www.mdpi.com/2072-6694/14/1/209

3. “Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatolog”
by Esnault Clara, David Schrama, Roland Houben, Serge Guyétant, Audrey Desgranges, Camille Martin, Patricia Berthon, Marie-Claude Viaud-Massuard, Antoine Touzé, Thibault Kervarrec et al.
Cancers 2022, 14(3), 778; https://doi.org/10.3390/cancers14030778
Available online: https://www.mdpi.com/2072-6694/14/3/778

4. “Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance”
by Reita Damien, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux and Michèle Beau-Faller
Cancers 2022, 14(5), 1321; https://doi.org/10.3390/cancers14051321
Available online: https://www.mdpi.com/2072-6694/14/5/1321

5. “Upregulation of CD36, a Fatty Acid Translocase, Promotes Colorectal Cancer Metastasis by Increasing MMP28 and Decreasing E-Cadherin Expression”
by Drury James, Piotr G. Rychahou, Courtney O. Kelson, Mariah E. Geisen, Yuanyuan Wu, Daheng He, Chi Wang, Eun Y. Lee, B. Mark Evers and Yekaterina Y. Zaytseva
Cancers 2022, 14(1), 252; https://doi.org/10.3390/cancers14010252
Available online: https://www.mdpi.com/2072-6694/14/1/252

6. “The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy”
by Canale Matteo, Kalliopi Andrikou, Ilaria Priano, Paola Cravero, Luigi Pasini, Milena Urbini, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte and Paola Ulivi
Cancers 2022, 14(5), 1143; https://doi.org/10.3390/cancers14051143
Available online: https://www.mdpi.com/2072-6694/14/5/1143

7. “High-Mannose N-Glycans as Malignant Progression Markers in Early-Stage Colorectal Cancer”
by Boyaval Fanny, Hans Dalebout, René Van Zeijl, Wenjun Wang, Arantza Fariña-Sarasqueta, Guinevere S. M. Lageveen-Kammeijer, Jurjen J. Boonstra, Liam A. McDonnell, Manfred Wuhrer, Hans Morreau et al.
Cancers 2022, 14(6), 1552; https://doi.org/10.3390/cancers14061552
Available online: https://www.mdpi.com/2072-6694/14/6/1552

8. “Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression”
by Danielle J. Fassler, Luke A. Torre-Healy, Rajarsi Gupta, Alina M. Hamilton, Soma Kobayashi, Sarah C. Van Alsten, Yuwei Zhang, Tahsin Kurc, Richard A. Moffitt, Melissa A. Troester et al.
Cancers 2022, 14(9), 2148; https://doi.org/10.3390/cancers14092148
Available online: https://www.mdpi.com/2072-6694/14/9/2148

9. “Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer”
by Roberto Corchado-Cobos, Natalia García-Sancha, Marina Mendiburu-Eliçabe, Aurora Gómez-Vecino, Alejandro Jiménez-Navas, Manuel Jesús Pérez-Baena, Marina Holgado-Madruga, Jian-Hua Mao, Javier Cañueto, Sonia Castillo-Lluva et al.
Cancers 2022, 14(2), 322; https://doi.org/10.3390/cancers14020322
Available online: https://www.mdpi.com/2072-6694/14/2/322

10. “Circular RNAs Modulate Cancer Hallmark and Molecular Pathways to Support Cancer Progression and Metastasis”
by Aliaksandr A. Yarmishyn, Afeez Adekunle Ishola, Chieh-Yu Chen, Nalini Devi Verusingam, Vimalan Rengganaten, Habeebat Aderonke Mustapha, Hao-Kai Chuang, Yuan-Chi Teng, Van Long Phung, Po-Kuei Hsu et al.
Cancers 2022, 14(4), 862; https://doi.org/10.3390/cancers14040862
Available online: https://www.mdpi.com/2072-6694/14/4/862

1. "Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies"
by Md. Sanower Hossain, Hidayah Karuniawati, Ammar Abdulrahman Jairoun, Zannat Urbi, Der Jiun Ooi, Akbar John, Ya Chee Lim, K. M. Kaderi Kibria, A. K. M. Mohiuddin, Long Chiau Ming et al.
Cancers 2022, 14(7), 1732; https://doi.org/10.3390/cancers14071732
Available online: https://www.mdpi.com/2072-6694/14/7/1732

2. "Anaplastic Thyroid Carcinoma: An Update"
by Arnaud Jannin, Alexandre Escande, Abir Al Ghuzlan, Pierre Blanchard, Dana Hartl, Benjamin Chevalier, Frédéric Deschamps, Livia Lamartina, Ludovic Lacroix, Corinne Dupuy et al.
Cancers 2022, 14(4), 1061; https://doi.org/10.3390/cancers14041061
Available online: https://www.mdpi.com/2072-6694/14/4/1061

3. "Current and Developing Liquid Biopsy Techniques for Breast Cancer"
by Hsing-Ju Wu and Pei-Yi Chu
Cancers 2022, 14(9), 2052; https://doi.org/10.3390/cancers14092052
Available online: https://www.mdpi.com/2072-6694/14/9/2052

4. "PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area"
by Antoine Verger, Aurélie Kas, Jacques Darcourt and Eric Guedj
Cancers 2022, 14(5), 1103; https://doi.org/10.3390/cancers14051103
Available online: https://www.mdpi.com/2072-6694/14/5/1103

5. "Phototheranostics of Cervical Neoplasms with Chlorin e6 Photosensitizer"
by Aida Gilyadova, Anton Ishchenko, Artem Shiryaev, Polina Alekseeva, Kanamat Efendiev, Radmila Karpova, Maxim Loshchenov, Victor Loschenov and Igor Reshetov
Cancers 2022, 14(1), 211; https://doi.org/10.3390/cancers14010211
Available online: https://www.mdpi.com/2072-6694/14/1/211

6. "Microwave Ablation for Colorectal Liver Metastases: A Systematic Review and Pooled Oncological Analyses"
by Antonio Mimmo, Francesca Pegoraro, Rami Rhaiem, Roberto Montalti, Alix Donadieu, Ahmad Tashkandi, Abdul Rahman Al-Sadairi, Reza Kianmanesh and Tullio Piardi
Cancers 2022, 14(5), 1305; https://doi.org/10.3390/cancers14051305
Available online: https://www.mdpi.com/2072-6694/14/5/1305

7. "Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?"
by Camilo Jimenez, Gustavo Armaiz-Pena, Patricia L. M. Dahia, Yang Lu, Rodrigo A. Toledo, Jeena Varghese and Mouhammed Amir Habra
Cancers 2022, 14(3), 467; https://doi.org/10.3390/cancers14030467
Available online: https://www.mdpi.com/2072-6694/14/3/467

8. "Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives"
by Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, Veronica Mollica, Ursula Maria Vogl, Laura Marandino, Francesco Massari, Ricardo Pereira Mestre, Elisa Zanardi, Alessio Signori et al.
Cancers 2022, 14(5), 1245; https://doi.org/10.3390/cancers14051245
Available online: https://www.mdpi.com/2072-6694/14/5/1245

9. "Application of Artificial Intelligence in Lung Cancer"
by Hwa-Yen Chiu, Heng-Sheng Chao and Yuh-Min Chen
Cancers 2022, 14(6), 1370; https://doi.org/10.3390/cancers14061370
Available online: https://www.mdpi.com/2072-6694/14/6/1370

10. "Prediction of Breast Cancer Histological Outcome by Radiomics and Artificial Intelligence Analysis in Contrast-Enhanced Mammography"
by Antonella Petrillo, Roberta Fusco, Elio Di Bernardo, Teresa Petrosino, Maria Luisa Barretta, Annamaria Porto, Vincenza Granata, Maurizio Di Bonito, Annarita Fanizzi, Raffaella Massafra et al.
Cancers 2022, 14(9), 2132; https://doi.org/10.3390/cancers14092132
Available online: https://www.mdpi.com/2072-6694/14/9/2132

On 9 February 2023, Clarivate, a global leader in providing trusted insights and analytics, added the Preprint Citation Index to the Web of Science platform, streamlining the research process by allowing researchers to locate and link to preprints alongside other trusted content in the database.

The Preprint Citation Index will act as a bridge to connect cutting-edge preprints with peer-reviewed journal articles published within the Web of Science Core Collection. Alerts can be easily set to monitor new research across several repositories and authors will also be able to include preprints on their Web of Science Research Profile to more accurately display their various research outputs.

As of its launch, the Preprint Citation Index will provide nearly two million preprints from various repositories, including MDPI’s own Preprints.org.

MDPI's Preprints Platform – Preprints.org

To advance Open Science and the fast dissemination of research, MDPI offers researchers a free multidisciplinary preprint platform. Preprints.org accepts submissions from all research areas and offers authors high visibility, permanent archiving, article-level Metrics and immediately citable content by assigning a Digital Object Identifier (DOI) to all preprints.

During submission to any MDPI journal, authors have the option to share their research as a preprint. After an initial screening, the manuscript is available online in 48 hours or less. Once online, preprints can be downloaded, shared, commented on, and cited, providing authors maximum visibility.

We invite you to join the ranks of the over 100k researchers using Preprints.org and share your research.

For more information, please visit Preprints.org.

1. “Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances”
by Blanca Cucarull, Anna Tutusaus, Patricia Rider, Tania Hernáez-Alsina, Carlos Cuño, Pablo García de Frutos, Anna Colell, Montserrat Marí and Albert Morales
Cancers 2022, 14(3), 621; https://doi.org/10.3390/cancers14030621
Available online: https://www.mdpi.com/2072-6694/14/3/621

2. “The Evolution of Ovarian Carcinoma Subclassification”
by Martin Köbel and Eun Young Kang
Cancers 2022, 14(2), 416; https://doi.org/10.3390/cancers14020416
Available online: https://www.mdpi.com/2072-6694/14/2/416

3. “Chemotherapy Side-Effects: Not All DNA Damage Is Equal”
by Winnie M. C. van den Boogaard, Daphne S. J. Komninos and Wilbert P. Vermeij
Cancers 2022, 14(3), 627; https://doi.org/10.3390/cancers14030627
Available online: https://www.mdpi.com/2072-6694/14/3/627

4. “The Role of Artificial Intelligence in Early Cancer Diagnosis”
by Benjamin Hunter, Sumeet Hindocha and Richard W. Lee
Cancers 2022, 14(6), 1524; https://doi.org/10.3390/cancers14061524
Available online: https://www.mdpi.com/2072-6694/14/6/1524

5. “Energy Sources for Exosome Communication in a Cancer Microenvironment”
by Abhimanyu Thakur, Amanda Johnson, Emily Jacobs, Kui Zhang, Jonathan Chen, Zhubo Wei, Qizhou Lian and Huanhuan Joyce Chen
Cancers 2022, 14(7), 1698; https://doi.org/10.3390/cancers14071698
Available online: https://www.mdpi.com/2072-6694/14/7/1698

6. “Fatty Acid Metabolism in Myeloid-Derived Suppressor Cells and Tumor-Associated Macrophages: Key Factor in Cancer Immune Evasion”
by Sophiya Siddiqui and Rainer Glauben
Cancers 2022, 14(1), 250; https://doi.org/10.3390/cancers14010250
Available online: https://www.mdpi.com/2072-6694/14/1/250

7. “Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer”
by Martín Núñez Abad, Silvia Calabuig-Fariñas, Miriam Lobo de Mena, Susana Torres-Martínez, Clara García González, José Ángel García García, Vega Iranzo González-Cruz and Carlos Camps Herrero
Cancers 2022, 14(2), 307; https://doi.org/10.3390/cancers14020307
Available online: https://www.mdpi.com/2072-6694/14/2/307

8. “Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers”
by Guillaume Anthony Odri, Joëlle Tchicaya-Bouanga, Diane Ji Yun Yoon and Dominique Modrowski
Cancers 2022, 14(2), 360; https://doi.org/10.3390/cancers14020360
Available online: https://www.mdpi.com/2072-6694/14/2/360

9. “EOB-MR Based Radiomics Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases”
by Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Sergio Venanzio Setola, Federica Dell’Aversana, Alessandro Ottaiano, Guglielmo Nasti, Roberta Grassi, Vincenzo Pilone et al.
Cancers 2022, 14(5), 1239; https://doi.org/10.3390/cancers14051239
Available online: https://www.mdpi.com/2072-6694/14/5/1239

10. “Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma”
by Marco Y. W. Zaki, Ahmed M. Fathi, Samara Samir, Nardeen Eldafashi, Kerolis Y. William, Maiiada Hassan Nazmy, Moustafa Fathy, Upkar S. Gill and Shishir Shetty
Cancers 2022, 14(5), 1255; https://doi.org/10.3390/cancers14051255
Available online: https://www.mdpi.com/2072-6694/14/5/1255

1. “Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021”
by Maroun Bou Zerdan, Tala Ghorayeb, Fares Saliba, Sabine Allam, Morgan Bou Zerdan, Marita Yaghi, Nadeem Bilani, Rola Jaafar and Zeina Nahleh
Cancers 2022, 14(5), 1253; https://doi.org/10.3390/cancers14051253
Available online: https://www.mdpi.com/2072-6694/14/5/1253

2. “MMP9: A Tough Target for Targeted Therapy for Cancer”
by Katarzyna Augoff, Anita Hryniewicz-Jankowska, Renata Tabola and Kamilla Stach
Cancers 2022, 14(7), 1847; https://doi.org/10.3390/cancers14071847
Available online: https://www.mdpi.com/2072-6694/14/7/1847

3. “Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers”
by Lindsey Carlsen, Kelsey E. Huntington and Wafik S. El-Deiry
Cancers 2022, 14(4), 1028; https://doi.org/10.3390/cancers14041028
Available online: https://www.mdpi.com/2072-6694/14/4/1028

4. “Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic”
by Ana Isabel Fraguas-Sánchez, Irene Lozza and Ana Isabel Torres-Suárez
Cancers 2022, 14(5), 1198; https://doi.org/10.3390/cancers14051198
Available online: https://www.mdpi.com/2072-6694/14/5/1198

5. “The Renaissance of Cyclin Dependent Kinase Inhibitors”
by Tobias Ettl, Daniela Schulz and Richard Josef Bauer
Cancers 2022, 14(2), 293; https://doi.org/10.3390/cancers14020293
Available online: https://www.mdpi.com/2072-6694/14/2/293

6. “Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms”
by Daisuke Takayanagi, Hourin Cho, Erika Machida, Atsushi Kawamura, Atsuo Takashima, Satoshi Wada, Takuya Tsunoda, Takashi Kohno and Kouya Shiraishi
Cancers 2022, 14(5), 1119; https://doi.org/10.3390/cancers14051119
Available online: https://www.mdpi.com/2072-6694/14/5/1119

7. “PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities”
by Hao-Wen Sim, Evanthia Galanis and Mustafa Khasraw
Cancers 2022, 14(4), 1003; https://doi.org/10.3390/cancers14041003
Available online: https://www.mdpi.com/2072-6694/14/4/1003

8. “Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2”
by Swati Misri, Kirti Kaul, Sanjay Mishra, Manish Charan, Ajeet Kumar Verma, Martin P. Barr, Dinesh K. Ahirwar and Ramesh K. Ganju
Cancers 2022, 14(5), 1181; https://doi.org/10.3390/cancers14051181
Available online: https://www.mdpi.com/2072-6694/14/5/1181

9. “Early Response Prediction of Multiparametric Functional MRI and 18F-FDG-PET in Patients with Head and Neck Squamous Cell Carcinoma Treated with (Chemo)Radiation”
by Roland M. Martens, Thomas Koopman, Cristina Lavini, Tim van de Brug, Gerben J. C. Zwezerijnen, J. Tim Marcus, Marije R. Vergeer, C. René Leemans, Remco de Bree, Pim de Graaf et al.
Cancers 2022, 14(1), 216; https://doi.org/10.3390/cancers14010216
Available online: https://www.mdpi.com/2072-6694/14/1/216

10. “Knowns and Unknowns about CAR-T Cell Dysfunction”
by Aleksei Titov, Yaroslav Kaminskiy, Irina Ganeeva, Ekaterina Zmievskaya, Aygul Valiullina, Aygul Rakhmatullina, Alexey Petukhov, Regina Miftakhova, Albert Rizvanov and Emil Bulatov
Cancers 2022, 14(4), 1078; https://doi.org/10.3390/cancers14041078
Available online: https://www.mdpi.com/2072-6694/14/4/1078

1. “Classification of Breast Cancer Nottingham Prognostic Index Using High-Dimensional Embedding and Residual Neural Network”
by Li Zhou, Maria Rueda and Abedalrhman Alkhateeb
Cancers 2022, 14(4), 934; https://doi.org/10.3390/cancers14040934
Available online: https://www.mdpi.com/2072-6694/14/4/934

2. “Bias and Class Imbalance in Oncologic Data—Towards Inclusive and Transferrable AI in Large Scale Oncology Data Sets”
by Erdal Tasci, Ying Zhuge, Kevin Camphausen and Andra V. Krauze
Cancers 2022, 14(12), 2897; https://doi.org/10.3390/cancers14122897
Available online: https://www.mdpi.com/2072-6694/14/12/2897

3. “Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of Tumorigenesis”
by Limin Jiang, Hui Yu, Scott Ness, Peng Mao, Fei Guo, Jijun Tang and Yan Guo
Cancers 2022, 14(2), 415; https://doi.org/10.3390/cancers14020415
Available online: https://www.mdpi.com/2072-6694/14/2/415

4. “Single-Cell Sequencing: Current Applications in Precision Onco-Genomics and Cancer Therapeutics”
by Lisa Maria Mustachio and Jason Roszik
Cancers 2022, 14(3), 657; https://doi.org/10.3390/cancers14030657
Available online: https://www.mdpi.com/2072-6694/14/3/657

5. “Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer”
by Parisa Forouzannezhad, Dominic Maes, Daniel S. Hippe, Phawis Thammasorn, Reza Iranzad, Jie Han, Chunyan Duan, Xiao Liu, Shouyi Wang, W. Art Chaovalitwongse et al.
Cancers 2022, 14(5), 1228; https://doi.org/10.3390/cancers14051228
Available online: https://www.mdpi.com/2072-6694/14/5/1228

6. “Identification of a Novel Cuproptosis-Related Gene Signature for Prognostic Implication in Head and Neck Squamous Carcinomas”
by Shouyi Tang, Li Zhao, Xing-Bo Wu, Zhen Wang, Lu-Yao Cai, Dan Pan, Ying Li, Yu Zhou and Yingqiang Shen
Cancers 2022, 14(16), 3986; https://doi.org/10.3390/cancers14163986
Available online: https://www.mdpi.com/2072-6694/14/16/3986

7. “An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)”
by Xuanyou Liu, Hao Wu and Zhenguo Liu
Cancers 2022, 14(11), 2658; https://doi.org/10.3390/cancers14112658
Available online: https://www.mdpi.com/2072-6694/14/11/2658

8. “Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer”
by Ji-Yong Sung and Jae-Ho Cheong
Cancers 2022, 14(13), 3191; https://doi.org/10.3390/cancers14133191
Available online: https://www.mdpi.com/2072-6694/14/13/3191

9. “Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds”
by Haoming Mai, Haisheng Xie, Mengqi Luo, Jia Hou, Jiaxuan Chen, Jinlin Hou and De-ke Jiang
Cancers 2022, 14(3), 563; https://doi.org/10.3390/cancers14030563
Available online: https://www.mdpi.com/2072-6694/14/3/563

10. “UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia”
by Lisa Weijler, Florian Kowarsch, Matthias Wödlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich and Michael N. Dworzak
Cancers 2022, 14(4), 898; https://doi.org/10.3390/cancers14040898
Available online: https://www.mdpi.com/2072-6694/14/4/898

1. “Epidemiology of Glioblastoma Multiforme–Literature Review“
by Szymon Grochans, Anna Maria Cybulska, Donata Simińska, Jan Korbecki, Klaudyna Kojder, Dariusz Chlubek and Irena Baranowska-Bosiacka
Cancers 2022, 14(10), 2412; https://doi.org/10.3390/cancers14102412
Available online: https://www.mdpi.com/2072-6694/14/10/2412

2. “Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer”
by Michael LaPelusa, Chan Shen, Nina D. Arhin, Dana Cardin, Marcus Tan, Kamran Idrees, Sunil Geevarghese, Bapsi Chakravarthy, Jordan Berlin and Cathy Eng
Cancers 2022, 14(2), 283; https://doi.org/10.3390/cancers14020283
Available online: https://www.mdpi.com/2072-6694/14/2/283

3. “Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study”
by Junjie Huang, Wing Chung Chan, Chun Ho Ngai, Veeleah Lok, Lin Zhang, Don Eliseo Lucero-Prisno III, Wanghong Xu, Zhi-Jie Zheng, Edmar Elcarte, Mellissa Withers et al.
Cancers 2022, 14(9), 2230; https://doi.org/10.3390/cancers14092230
Available online: https://www.mdpi.com/2072-6694/14/9/2230

4. “Febrile Neutropenia Duration Is Associated with the Severity of Gut Microbiota Dysbiosis in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients”
by Riccardo Masetti, Federica D’Amico, Daniele Zama, Davide Leardini, Edoardo Muratore, Marek Ussowicz, Jowita Fraczkiewicz, Simone Cesaro, Giulia Caddeo, Vincenza Pezzella et al.
Cancers 2022, 14(8), 1932; https://doi.org/10.3390/cancers14081932
Available online: https://www.mdpi.com/2072-6694/14/8/1932

5. “Slip versus Slop: A Head-to-Head Comparison of UV-Protective Clothing to Sunscreen”
by Elizabeth G. Berry, Joshua Bezecny, Michael Acton, Taylor P. Sulmonetti, David M. Anderson, Haskell W. Beckham, Rebecca A. Durr, Takahiro Chiba, Jennifer Beem, Douglas E. Brash et al.
Cancers 2022, 14(3), 542; https://doi.org/10.3390/cancers14030542
Available online: https://www.mdpi.com/2072-6694/14/3/542

6. “Unmet Needs and Perspectives in Oral Cancer Prevention”
by Jebrane Bouaoud, Paolo Bossi, Moshe Elkabets, Sandra Schmitz, Léon C. van Kempen, Pierre Martinez, Sankar Jagadeeshan, Ingrid Breuskin, Gerwin J. Puppels, Caroline Hoffmann et al.
Cancers 2022, 14(7), 1815; https://doi.org/10.3390/cancers14071815
Available online: https://www.mdpi.com/2072-6694/14/7/1815

7. “New Insights into the Epidemiology of Vulvar Cancer: Systematic Literature Review for an
Update of Incidence and Risk Factors”
by Lauro Bucchi, Margherita Pizzato, Stefano Rosso and Stefano Ferretti
Cancers 2022, 14(2), 389; https://doi.org/10.3390/cancers14020389
Available online: https://www.mdpi.com/2072-6694/14/2/389

8. “The Impact of Treatment for Smoking on Breast Cancer Patients’ Survival”
by Akshara Singareeka Raghavendra, George Kypriotakis, Maher Karam-Hage, Seokhun Kim, Mazen Jizzini, Kareem S. Seoudy, Jason D. Robinson, Carlos H. Barcenas, Paul M. Cinciripini, Debu Tripathy et al.
Cancers 2022, 14(6), 1464; https://doi.org/10.3390/cancers14061464
Available online: https://www.mdpi.com/2072-6694/14/6/1464

9. “Vet-ICD-O-Canine-1, a System for Coding Canine Neoplasms Based on the Human ICD-O-3.2”
by Katia Pinello, Valeria Baldassarre, Katja Steiger, Orlando Paciello, Isabel Pires, Renée Laufer-Amorim, Anna Oevermann, João Niza-Ribeiro, Luca Aresu, Brian Rous et al.
Cancers 2022, 14(6), 1529; https://doi.org/10.3390/cancers14061529
Available online: https://www.mdpi.com/2072-6694/14/6/1529

10. “Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN)”
by Marcela Guevara, Amaia Molinuevo, Diego Salmerón, Rafael Marcos-Gragera, Marià Carulla, María-Dolores Chirlaque, Marta Rodríguez Camblor, Araceli Alemán, Dolores Rojas, Ana Vizcaíno Batllés et al.
Cancers 2022, 14(10), 2441; https://doi.org/10.3390/cancers14102441
Available online: https://www.mdpi.com/2072-6694/14/10/2441

We are delighted to announce that Prof. Dr. Sanjay K. Srivastava, M.S., Ph.D., FAAAS, has become the new Section Editor-in-Chief of the Section “Cancer Metastasis” in Cancers (ISSN: 2072-6694).

Prof. Dr. Sanjay K. Srivastava is a University Distinguished Professor, the Chairman of the Department of Immunotherapeutics and Biotechnology, and the Associate Dean for Graduate Programs at the Texas Tech University Health Sciences Center (TTUHSC). He is also a James ‘Buddy’ Davidson Endowed Professor of Pediatric Pharmacology and Oncology. Prof. Dr. Srivastava also served as the Associate Dean for Research for six years at TTUHSC. He recently received the honor to be elected as the Fellow of the American Association for the Advancement of Science (AAAS), which is a very prestigious scientific organization.

Prof. Dr. Srivastava has extensive research experience in the field of cancer chemoprevention and therapeutics. He is a serial innovator with several patents to his credit. His inventive contributions are supported by excellence in research. Named in the World’s Top 2% Scientists list for 2020 and 2021, Prof. Dr. Srivastava has a track record of being a productive scientist, authoring more than 160 research articles in high-impact journals with more than 10,000 citations and holding an H-index of 57, demonstrating just how impactful his research contributions have been over the years. His research has been funded by the National Cancer Institute, NIH, and other agencies and he has received numerous prestigious awards. The major focus of his laboratory is on delineating the signaling mechanisms responsible for tumor growth, angiogenesis, and metastasis in different cancer models including pancreatic, ovarian, breast, melanoma, and glioblastoma. His recent research focuses on understanding the mechanism of chemotherapeutic drug resistance in melanoma, breast, and glioblastoma. For the last 10+ years, he has also been repurposing existing non-cancer drugs for cancer therapy. For example, his group has demonstrated the anticancer effects of a few anti-psychotic drugs for breast cancer, brain cancer, and pancreatic cancer therapy. He also outlined the anti-tumor effects of anti-malarial and anti-helminthic drugs for drug-resistant breast cancer.

Prof. Dr. Srivastava has mentored numerous trainees (undergraduate students, post-doctoral fellows, and graduate students) who are now established researchers/faculty at different places. His research has been highlighted by media and news agencies. Prof. Dr. Srivastava is on the editorial board of several prestigious journals and is a member of societies including AACR, SOT, AAAS, and AAPS. He serves on the grant review panels of the National Institute of Health (NIH), the Department of Defense, and other agencies.

The following is a short Q&A with Prof. Dr. Srivastava, who shared his vision for the journal with us, as well as his views of the research area and Open Access publishing:

1. What appealed to you about the journal that made you want to take the role as its Editor-in-Chief?

I am a well-established cancer researcher and have published a few articles in Cancers. I realized that Cancers was lacking one of the key hallmarks of cancer, metastasis, so I decided to establish a separate Section for “Cancer Metastasis”. With my 30 years of research experience in the field of cancer and over 160 publications, I can contribute significantly to this Section.

I would like to expand this Section and would like to see it become one of the top-rated journal Sections on cancer metastasis.

Although a lot of groundbreaking discoveries have been made, there is still a lot to know about cancer and appropriate drugs to be found for therapy, especially for metastatic tumors.

The benefit of Open Access journals is that they are easily accessible to people across the globe.

We warmly welcome Prof. Dr. Sanjay K. Srivastava as the new Section Editor-in-Chief and we look forward to him leading Cancers to reach many more milestones.

Recently, Clarivate^TM revealed its 2022 list of Highly Cited Researchers™—individuals at universities, research institutes and commercial organizations.

The scientists who were selected for this year’s list of Highly Cited Researchers have published highly cited papers in the 11-year period from January 2011 to December 2021, with a citation frequency in the top 1% of academic subjects and the same year of publication in the Web of Science^TM database. Based on the Web of Science Citation data, 6938 researchers from across the globe who have demonstrated a disproportionate level of significant and broad influence in their chosen field or fields over the last decade have been awarded Highly Cited Researcher 2022 designations. The list is truly global, spanning 69 countries or regions and spread across a diverse range of research sciences and social sciences.

According to statistics, 27 members of the Editorial Board of Cancers (ISSN: 2072-6694) have been listed among the Highly Cited Researchers by Clarivate in 2022. They are being recognized for their high-quality scientific research achievements and outstanding contributions to professional fields. The Cancers journal office sincerely congratulates all elected Editorial Board Members and hopes that they continue to have an academically productive relationship with the journal.

We are pleased to announce the launch of a new initiative—the MDPI Special Issue Mentor Program.

This program will enable early career researchers (who must hold a Ph.D. in a related field) to experience editing a Special Issue in MDPI journals, under the mentorship of our experienced Editorial Board Members or other experienced scientists. The mentor program will provide an excellent opportunity for early career scientists to gain editorial experience, and to cultivate their ability to edit scientific research.

The mentee’s responsibilities include:

• Proposing a Special Issue title and assisting the mentor in preparing a summary (around 200–400 words) and 3–10 keywords describing the background, importance, and goal of the Issue;
• Writing a brief promotion plan for the Special Issue;
• Preparing a list of scholars who may be interested in the Issue and personally e-mailing invitations on behalf of Guest Editors;
• Writing an editorial for the online Special Issue together with the mentor.

The mentor’s responsibilities include:

• Conducting a final check before the Special Issue is published online;
• Performing editorial control of the Special Issue and quality control of the publications, both of which must be carried out in a timely manner;
• Providing suggestions to younger scholars if they have any doubts or concerns regarding submissions;
• Organizing video calls with young scholars and the Editorial Office regularly to discuss problems and improvement suggestions for the Special Issue;
• Making and submitting decisions regarding submissions with the assistance of mentees.

Certificates and awards:
After the Special Issue closes, the Editorial Office will provide official certificates for all the mentors and early career researchers.

If you are interested in this opportunity, please send your Special Issue proposal to the Editorial Office of a journal you choose, and we will discuss the process (i.e., mentor collaboration, Special Issue topic feasibility analysis, etc.) in further detail. The full list of MDPI journals is as follows: https://www.mdpi.com/about/journals.

In addition to the new Special Issue Mentor Program, we will continue to welcome all Special Issue proposals focusing on hot research topics.

MDPI has just become the first open access (OA) publisher to reach the milestone of one million articles published. That is one million articles freely available to all, to circulate and build upon! We are proud to share this special moment with the global scientific community.

This landmark has been reached thanks to the immeasurable support of more than 600,000 expert reviewers, 66,000 editorial board members and 6700 hard-working colleagues across MDPI’s global offices.

Within more than 25 years of publishing, our journals received 2.1 million manuscripts and generated 4.6 million peer review reports to get to one million papers published.

Reaching the milestone of one million articles published reinforces our mission to remove any existing barriers and to make scientific research accessible to all. Since its inception, MDPI’s goal has been to create reliable processes to make science open. This is a path towards facilitating the dissemination of novel insights in scientific communities.

Regular feedback from authors and reviewers shows that our service is greatly appreciated and needed. At the same time, the feedback helps us identify areas for further improvement.

As it stands, a significant share of published research findings remain closed access. More than half of the content published with the most well-known legacy publishers stays behind a paywall, and that is not including articles published in hybrid OA journals, or made available months or years after publication.

A new policy announced by the US administration in August 2022 requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. While the new policy does not mandate articles be published under an open access license, it is aligned with the open access movement in removing all barriers to research. Similarly, some of the most advanced research institutions in the world intend to have all funded research articles published in open access by 2025.

MDPI is proud to be the leading agent of the transition to open access.

"Thanks a Million" to all the contributors!

We are delighted to announce that Dr. Maen Abdelrahim, MD, Ph.D., Pharm B, Associate Professor of Medicine, Weill Cornell Medical College, Associate Clinical Member, Houston Methodist Research Institute, Director, Cockrell Center for Advanced Therapeutics, Research Institute, has taken over as Section Editor-in-Chief of the Section “Transplant Oncology and Cancer Nursing Care” in Cancers (ISSN: 2072-6694). 

Dr. Maen Abdelrahim is a gastrointestinal medical oncologist and transplant oncologist attending to patients with upper and lower GI malignancies in addition to malignancies treated by liver transplantation. He is the section chief of GI medical oncology leading GI cancer care at Houston Methodist Neal Cancer Center with a focus on clinical trial Phase II/III in GI malignancies. Dr. Abdelrahim serves as the medical director of the Cockrell Center for Advanced Therapeutics where he oversees the Phase I program at Houston Methodist Hospital and Neal Cancer Center. He is a principal investigator on multiple clinical trials with a focus on chemotherapy, targeted therapy, and immunotherapy in GI malignancies. His translational research is focused on developing new mechanism-based drugs for the treatment of gastrointestinal cancers. He has identified for the first time a new structural class of compounds that can target selective transcription factors that is now recognized as a candidate for the development of new anticancer drugs. The lead compound of this class reached Phase I clinical trial to treat patients with GI cancers.

Dr. Maen Abdelrahim's research has pinpointed a number of compounds that inhibit tumor growth and angiogenesis, in part by inducing proteasome-dependent degradation of selected Sp proteins in cancer cells and tumors. The lead compound of this class (Tolfenamic acid) has reached Phase I clinical trial to treat patients with advanced and metastatic pancreatic cancer in combination with gemcitabine and radiation therapy. Dr. Abdelrahim has a patent application submitted for the new use of these compounds in GI cancers. In prior research, he was the first to discover that Sp4 protein is overexpressed in GI cancers, including pancreatic cancer, and that the role of Sp4 can be equally as important as Sp1 in some types of GI cancers.

Researchers in cancer have the ultimate responsibility of taking their findings to the clinic, which is described as translational research. By seeing GI cancer patients in his practice, collaborating with translational scientists in the lab and conducting and directing clinical trials, Dr. Maen Abdelrahim hopes to continue to fuel the translational research cycle from lab to clinic and back to the lab. Dr. Abdelrahim has published more than 220 original research articles, abstracts, review articles, and book chapters in prestigious journals and publishing groups. He is a member of the American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Cholangiocarcinoma Foundation, European Society for Medical Oncology, and International Liver Transplant Society. He is the site principal investigator for the Southwest Oncology Cooperative Group at Houston Methodist Neal Cancer Center.

Dr. Maen Abdelrahim completed his pharmacy degree followed by a Ph.D. and graduate work in the field of pharmacology and toxicology from Texas A&M University, College Station, Texas. He obtained his medical degree from Texas A&M University, completed his residency at Baylor College of Medicine, and a fellowship in medical oncology at Duke University.

The following is a short Q&A with Dr. Maen Abdelrahim, who shared his vision for the journal with us, as well as his views of the research area:

1. What appealed to you about Cancers that made you want to take the role as its Section Editor-in-Chief?
What drew me to Cancers is its emphasis on openness and novelty in research by publishing studies on clinical translations, and basic science topics associated with cancer research. As an Editorial Board Member, reviewer, and contributor to Cancers, I have found it to be the best resource for information on the problems that affect oncology. One of those platforms that aid in guiding research in the right direction is Cancers; as well as guiding research in the right direction, Cancers’ emphasis on publishing results from around the world with the same enthusiasm strikes me as being the aspect that most closely aligns with my way of thinking. Publishing meaningful negative results with the same enthusiasm as positive results is another aspect of Cancers.

2. What is your vision for Cancers?
In the years to come, I hope to see Cancers serve as a forum for researchers and oncologists to share their knowledge and research findings. My goal is to make a difference in the field of cancer research by opening doors for fresh ideas and giving them the chance to present their work without just focusing on experiments' positive and negative outcomes. I would see this as a chance to inspire and encourage researchers to explain the reasoning behind their research and will make sure to add my expertise to every research or study I undertake.

3. What does the future of this field of research look like?
It is a well-known fact that the number of cancer patients has been increasing over the years; deaths from this disease are very visible, and these numbers are expected to rise further in the coming years. According to statistics, implementing cancer prevention strategies can prevent half to two-thirds of all cancer cases. Once the potential of this field is realized, the battle against cancer will be half won, and lethal exposure to existing cancer therapies will be eliminated. As a result, it is critical to prioritize cancer research and expand its reach.

4. What do you think of the development of Open Access in the publishing field?
In my opinion, there should be no obstacles between science and readers. It should be open to all with no restrictions. Furthermore, as this research field gains traction, it would benefit a larger population if the progress was transparent and accessible to all newcomers in this field.

We warmly welcome Dr. Maen Abdelrahim to his new role as Section Editor-in-Chief, and we look forward to him leading Cancers to many more milestones.

We are pleased to announce that the website of the MDPI Sustainability Foundation has been revamped! For the past couple of months, our UX UI team and front-end developers have been working hard to launch the website in time for the opening of the Sustainability Awards nominations.

The website is not the only thing that has had a remodeling. Indeed, the format of the Emerging Sustainability Leader Award (ESLA) has been updated. ESLA is now a competition open to individual researchers or start-ups founded by researchers under the age of 35. Nominee applications will go through 2 rounds of selection until the final 3 are decided. The finalists will then be invited to give pitch presentations during the Award Ceremony to win either first place (10,000 USD) or runner-up (2 x 5000 USD).

The World Sustainability Award, on the other hand, remains the same: a total prize money of 100,000 USD is up for grabs by senior individual researchers or groups of researchers from the international research community.

Nominations for both the World Sustainability Award and the Emerging Sustainability Leader award are now open! Check out our new website for more information on how to nominate.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Drug Development”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Drug Development”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Metastasis”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Metastasis”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

A range of MDPI journals will be attending the 15th Annual Meeting of Chinese Society for Immunology. This meeting will be held in Chongqing, China, from 27 to 30 December 2022.

The conference focuses on the following areas:

• Recognition and regulation of innate immune responses;
• Adaptive immune response;
• Immune metabolism and immune regulation;
• Immunity to COVID-19 infection;
• Tumor immunity and tumor immunotherapy;
• Autoimmune diseases and other topics.

The following MDPI journals will be represented:

• IJMS (leading journal);
• Vaccines;
• Metabolites;
• Cells;
• Cancers;
• Biomedicines;
• CIMB;
• Pathogens;
• Immuno.

If you plan on attending this conference, feel free to stop by our booth #B13. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please see the following link: https://csimeeting2022.sciconf.cn/cn/web/index/13562.  

Lung cancer is the most common malignancy in many parts of the world. It is often diagnosed late and has one of the poorest outcomes among other cancers. Recent studies (NELSON from Europe and NLST from USA) have shown that lung cancer screening via computed tomography scans can identify lung cancer at an earlier stage in certain populations, and reduce mortality. The diagnosis and management of these tumors, with many being small nodules or ground glass changes, remain a challenge. The landscape and management of lung cancer in general have also changed dramatically in the last decade, perhaps more than any other thoracic disease. Advances in surgery and cancer genetics facilitate personalized drug therapies that can provide ever more complex and innovative treatment algorithms to fight this terrible disease. The role of liquid biopsies, more targeted bespoke drug therapies, non-invasive endoscopic treatments, and high-precision surgeries are only some of the evolving horizons in lung cancer management.

November 2022 is designated as "World Lung Cancer Awareness Month", with various global activities that highlight and increase awareness of lung cancer for research support and development. We would like to share some of the high-quality and innovative research findings published in Cancers (ISSN: 2072-6694).

The list of relevant papers can be seen below:

“The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells”
by Dong Young Kang, Nipin Sp, Eun Seong Jo, Alexis Rugamba, Dae Young Hong, Hong Ghi Lee, Ji-Seung Yoo, Qing Liu, Kyoung-Jin Jang and Young Mok Yang
Available online: https://www.mdpi.com/2072-6694/12/3/727

“Extracellular Vesicle lincRNA-p21 Expression in Tumor-Draining Pulmonary Vein Defines Prognosis in NSCLC and Modulates Endothelial Cell Behavior”
by Joan J. Castellano, Ramon M. Marrades, Laureano Molins, Nuria Viñolas, Jorge Moises, Jordi Canals, Bing Han, Yan Li, Daniel Martinez, Mariano Monzó et al.
Available online: https://www.mdpi.com/2072-6694/12/3/734

“Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient”
by Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1125

“¹⁸F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival”
by Giulia Polverari, Francesco Ceci, Valentina Bertaglia, Maria Lucia Reale, Osvaldo Rampado, Elena Gallio, Roberto Passera, Virginia Liberini, Paola Scapoli, Vincenzo Arena et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1163

“Association of a CT-Based Clinical and Radiomics Score of Non-Small Cell Lung Cancer (NSCLC) with Lymph Node Status and Overall Survival”
by Francesca Botta, Sara Raimondi, Lisa Rinaldi, Federica Bellerba, Federica Corso, Vincenzo Bagnardi, Daniela Origgi, Rocco Minelli, Giovanna Pitoni, Francesco Petrella et al.
Available online: https://www.mdpi.com/2072-6694/12/6/1432

“Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab”
by Romain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, Marie-Ange Massiani, Michael Soussan, Gérald Bonardel, Christos Chouaid, Margot Playe, Lucas Goldfarb, Boris Duchemann et al.
Available online: https://www.mdpi.com/2072-6694/12/8/2234

“Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study”
by Pierre-Jean Lamy, Paul van der Leest, Nicolas Lozano, Catherine Becht, Frédérique Duboeuf, Harry J. M. Groen, Werner Hilgers, Nicolas Pourel, Naomi Rifaela, Ed Schuuring et al.
Available online: https://www.mdpi.com/2072-6694/12/10/3002

“Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies”
by Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow and Giandomenico Roviello
Available online: https://www.mdpi.com/2072-6694/12/11/3293

“A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC”
by Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson and Bilal Piperdi
Available online: https://www.mdpi.com/2072-6694/12/12/3648

“Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review”
by Alice Indini, Erika Rijavec and Francesco Grossi
Available online: https://www.mdpi.com/2072-6694/13/8/1794

You are welcome to submit relevant papers to the Special Issue “World Lung Cancer Awareness Month”.

Dr. Calvin Sze Hang Ng
Editorial Board Member of Cancers

Stanford University has recently published an update of the list of the top 2% most widely cited scientists. The time node of the statistical data of this list is from 1960 to 2022, and it is divided into two lists: "Lifetime Scientific Influence Ranking" and "2022 Annual Scientific Influence Ranking". The "Lifetime Scientific Influence Ranking" counts the comprehensive influence performance of scientists during their careers, and the "2022 Annual Influence Ranking" focuses on highlighting the academic influence of scientists in the previous year. This ranking, considered the most prestigious worldwide, is based on the bibliometric information contained in the Scopus database and includes more than 200,000 researchers from the more than 10 million scientists considered to be active worldwide, with 22 scientific fields and 176 subfields taken into account.

We are pleased to share that 670 Editorial Board Members from MDPI’s Cancers (ISSN: 2072-6694) were featured in Stanford University World’s Top 2% Scientists list in 2022.

The latest Stanford rankings reflect the significant influence and research excellence of the scientists, who are committed to furthering their knowledge for the benefit of the world.

We would like to congratulate our Editorial Board Members on their excellent achievement and thank them for their immense contribution to the scientific progression and development of Cancers. 

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Pediatric Oncology”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Pediatric Oncology”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Informatics and Big Data”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Informatics and Big Data”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

MDPI will be attending the 27th Congress of the Chinese Pediatric Society, held in Changsha, China, from 15–18 December 2022.

The following MDPI journals will be represented:

• Children (leading journal);
• JPM;
• Medicina;
• Audiology Research;
• JCM;
• Healthcare;
• Diagnostics;
• Metabolites;
• Cancers;
• Nutrients. 

If you plan on attending this conference, feel free to stop by our booth: #B67. Our delegates look forward to meeting you in person to answer any questions that you may have. 

For more information about the conference, please see the following link: https://nccps2022.tiemeeting.com/CN.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Infectious Agents and Cancer”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Infectious Agents and Cancer”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

1. “Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis”
by Usman, S.; Waseem, N. H.; Nguyen, T. K. N.; Mohsin, S.; Jamal, A.; Teh, M.-T. and Waseem, A.
Cancers 2021, 13(19), 4985; https://doi.org/10.3390/cancers13194985
Available online: https://www.mdpi.com/2072-6694/13/19/4985

2. “Prognostic Utility of Platelet–Lymphocyte Ratio, Neutrophil–Lymphocyte Ratio and Monocyte–Lymphocyte Ratio in Head and Neck Cancers: A Detailed PRISMA Compliant Systematic Review and Meta-Analysis”
by Kumarasamy, C.; Tiwary, V.; Sunil, K.; Suresh, D.; Shetty, S.; Muthukaliannan, G. K.; Baxi, S. and Jayaraj, R.
Cancers 2021, 13(16), 4166; https://doi.org/10.3390/cancers13164166
Available online: https://www.mdpi.com/2072-6694/13/16/4166

3. “Margin Assessment in Soft Tissue Sarcomas: Review of the Literature”
by Sambri, A.; Caldari, E.; Fiore, M.; Zucchini, R.; Giannini, C.; Pirini, M. G.; Spinnato, P.; Cappelli, A.; Donati, D. M. and De Paolis, M.
Cancers 2021, 13(7), 1687; https://doi.org/10.3390/cancers13071687
Available online: https://www.mdpi.com/2072-6694/13/7/1687

4. “Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review”
by Foerster, R.; Zwahlen, D. R.; Buchali, A.; Tang, H.; Schroeder, C.; Windisch, P.; Vu, E.; Akbaba, S.; Bostel, T.; Sprave, T.; Zamboglou, C.; Zilli, T.; Stelmes, J.-J.; Telkhade, T. and Murthy, V.  
Cancers 2021, 13(4), 759; https://doi.org/10.3390/cancers13040759
Available online: https://www.mdpi.com/2072-6694/13/4/759

5. “The Effects of Multidisciplinary Team Meetings on Clinical Practice for Colorectal, Lung, Prostate and Breast Cancer: A Systematic Review”
by Kočo, L.; Weekenstroo, H. H. A.; Lambregts, D. M. J.; Sedelaar, J. P. M.; Prokop, M.; Fütterer, J. J. and Mann, R. M.
Cancers 2021, 13(16), 4159; https://doi.org/10.3390/cancers13164159
Available online: https://www.mdpi.com/2072-6694/13/16/4159

6. “A Systematic Review of the Safety, Feasibility and Benefits of Exercise for Patients with Advanced Cancer”
by De Lazzari, N.; Niels, T.; Tewes, M. and Götte, M.
Cancers 2021, 13(17), 4478; https://doi.org/10.3390/cancers13174478
Available online: https://www.mdpi.com/2072-6694/13/17/4478

7. “Obesity as a Risk Factor for Prostate Cancer Mortality: A Systematic Review and Dose-Response Meta-Analysis of 280,199 Patients”
by Rivera-Izquierdo, M.; Pérez de Rojas, J.; Martínez-Ruiz, V.; Pérez-Gómez, B.; Sánchez, M.-J.; Khan, K. S. and Jiménez-Moleón, J. J.
Cancers 2021, 13(16), 4169; https://doi.org/10.3390/cancers13164169
Available online: https://www.mdpi.com/2072-6694/13/16/4169

8. “Radiomics Models for Predicting Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Radiomics Quality Score Assessment”
by Wang, Q.; Li, C.; Zhang, J.; Hu, X.; Fan, Y.; Ma, K.; Sparrelid, E. and Brismar, T. B.
Cancers 2021, 13(22), 5864; https://doi.org/10.3390/cancers13225864
Available online: https://www.mdpi.com/2072-6694/13/22/5864

9. “Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis”
by Horeweg, N.; Mittal, P.; Gradowska, P. L.; Boere, I.; Chopra, S. and Nout, R. A.
Cancers 2021, 13(8), 1880; https://doi.org/10.3390/cancers13081880
Available online: https://www.mdpi.com/2072-6694/13/8/1880

10. “Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies”
by Zahnreich, S. and Schmidberger, H.
Cancers 2021, 13(11), 2607; https://doi.org/10.3390/cancers13112607
Available online: https://www.mdpi.com/2072-6694/13/11/2607

1. “Novel Transfer Learning Approach for Medical Imaging with Limited Labeled Data”
by Alzubaidi, L.; Al-Amidie, M.; Al-Asadi, A.; Humaidi, A. J.; Al-Shamma, O.; Fadhel, M. A.; Zhang, J. L.; Santamaria, J. and Duan, Y.
Cancers 2021, 13(7), 1590; https://doi.org/10.3390/cancers13071590
Available online: https://www.mdpi.com/2072-6694/13/7/1590 

2. “Transfer Learning in Breast Cancer Diagnoses via Ultrasound Imaging”
by Ayana, G.; Dese, K. and Choe, S. W.
Cancers 2021, 13(4), 738; https://doi.org/10.3390/cancers13040738
Available online: https://www.mdpi.com/2072-6694/13/4/738

3. “Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal”
by Granata, V.; Caruso, D.; Grassi, R.; Cappabianca, S.; Reginelli, A.; Rizzati, R.; Masselli, G.; Golfieri, R.; Rengo, M.; Regge, D.; Lo Re, G.; Pradella, S.; Fusco, R.; Faggioni, L.; Laghi, A.; Miele, V.; Neri, E. and Coppola, F.
Cancers 2021, 13(9), 2135; https://doi.org/10.3390/cancers13092135
Available online: https://www.mdpi.com/2072-6694/13/9/2135

4. “Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions”
by Lawlor, R. T.; Mattiolo, P.; Mafficini, A.; Hong, S.-M.; Piredda, M. L.; Taormina, S. V.; Malleo, G.; Marchegiani, G.; Pea, A.; Salvia, R.; Kryklyva, V.; Shin, J. I.; Brosens, L. A.; Milella, M.; Scarpa, A. and Luchini, C.
Cancers 2021, 13(13), 3119; https://doi.org/10.3390/cancers13133119
Available online: https://www.mdpi.com/2072-6694/13/13/3119

5. “OmiEmbed: A Unified Multi-Task Deep Learning Framework for Multi-Omics Data”
by Zhang, X.; Xing, Y.; Sun, K. and Guo, Y.
Cancers 2021, 13(12), 3047; https://doi.org/10.3390/cancers13123047
Available online: https://www.mdpi.com/2072-6694/13/12/3047

6. “Identification of Cancer Hub Gene Signatures Associated with Immune-Suppressive Tumor Microenvironment and Ovatodiolide as a Potential Cancer Immunotherapeutic Agent”
by Chen, J.-H.; Wu, A. T. H.; Lawal, B.; Tzeng, D. T. W.; Lee, J.-C.; Ho, C.-L. and Chao, T.-Y.
Cancers 2021, 13(15), 3847; https://doi.org/10.3390/cancers13153847
Available online: https://www.mdpi.com/2072-6694/13/15/3847

7. “Nanopore Sequencing Reveals Global Transcriptome Signatures of Mitochondrial and Ribosomal Gene Expressions in Various Human Cancer Stem-like Cell Populations”
by Witte, K. E.; Hertel, O.; Windmöller, B. A.; Helweg, L. P.; Höving, A. L.; Knabbe, C.; Busche, T.; Greiner, J. F. W.; Kalinowski, J.; Noll, T.; Mertzlufft, F.; Beshay, M.; Pfitzenmaier, J.; Kaltschmidt, B.; Kaltschmidt, C.; Banz-Jansen, C. and Simon, M.
Cancers 2021, 13(5), 1136; https://doi.org/10.3390/cancers13051136
Available online: https://www.mdpi.com/2072-6694/13/5/1136

8. “Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia”
by Vial, J. P.; Lechevalier, N.; Lacombe, F.; Dumas, P.-Y.; Bidet, A.; Leguay, T.; Vergez, F.; Pigneux, A. and Béné, M.C.
Cancers 2021, 13(4), 629; https://doi.org/10.3390/cancers13040629
Available online: https://www.mdpi.com/2072-6694/13/4/629

9. “Homology-Based Image Processing for Automatic Classification of Histopathological Images of Lung Tissue”
by Nishio, M.; Nishio, M.; Jimbo, N. and Nakane, K.
Cancers 2021, 13(6), 1192; https://doi.org/10.3390/cancers13061192
Available online: https://www.mdpi.com/2072-6694/13/6/1192

10. “Convolutional Neural Network-Based Clinical Predictors of Oral Dysplasia: Class Activation Map Analysis of Deep Learning Results”
by Camalan, S.; Mahmood, H.; Binol, H.; Araújo, A. L. D.; Santos-Silva, A. R.; Vargas, P. A.; Lopes, M. A.; Khurram, S. A. and Gurcan, M. N.
Cancers 2021, 13(6), 1291; https://doi.org/10.3390/cancers13061291
Available online: https://www.mdpi.com/2072-6694/13/6/1291

1. “Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis”
by Luo, D.; Wang, X.; Burda, C. and Basilion, J. P.
Cancers 2021, 13(8), 1825; https://doi.org/10.3390/cancers13081825
Available online: https://www.mdpi.com/2072-6694/13/8/1825

2. “Radiomics-Derived Data by Contrast Enhanced Magnetic Resonance in RAS Mutations Detection in Colorectal Liver Metastases”
by Granata, V.; Fusco, R.; Avallone, A.; De Stefano, A.; Ottaiano, A.; Sbordone, C.; Brunese, L.; Izzo, F. and Petrillo, A.
Cancers 2021, 13(3), 453; https://doi.org/10.3390/cancers13030453
Available online: https://www.mdpi.com/2072-6694/13/3/453

3. “DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges”
by Sabir, F.; Zeeshan, M.; Laraib, U.; Barani, M.; Rahdar, A.; Cucchiarini, M. and Pandey, S.
Cancers 2021, 13(14), 3396; https://doi.org/10.3390/cancers13143396
Available online: https://www.mdpi.com/2072-6694/13/14/3396

4. “Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer”
by Hildebrand, L. A.; Pierce, C. J.; Dennis, M.; Paracha, M. and Maoz, A.
Cancers 2021, 13(3), 391; https://doi.org/10.3390/cancers13030391
Available online: https://www.mdpi.com/2072-6694/13/3/391

5. “Diagnostic Utility of the Immunohistochemical Expression of Serine and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas”
by Broggi, G.; Salvatorelli, L.; Barbagallo, D.; Certo, F.; Altieri, R.; Tirrò, E.; Massimino, M.; Vigneri, P.; Guadagno, E.; Maugeri, G.; D’Agata, V.; Musumeci, G.; Ragusa, M.; Barbagallo, G. M. V.; Russo, D. and Caltabiano, R.
Cancers 2021, 13(9), 2086; https://doi.org/10.3390/cancers13092086
Available online: https://www.mdpi.com/2072-6694/13/9/2086

6. “Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells”
by Dixon, K. J.; Wu, J. and Walcheck, B.
Cancers 2021, 13(2), 312; https://doi.org/10.3390/cancers13020312
Available online: https://www.mdpi.com/2072-6694/13/2/312

7. “Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study”
by Fanizzi, A.; Pomarico, D.; Paradiso, A.; Bove, S.; Diotaiuti, S.; Didonna, V.; Giotta, F.; La Forgia, D.; Latorre, A.; Pastena, M. I.; Tamborra, P.; Zito, A.; Lorusso, V. and Massafra, R.
Cancers 2021, 13(2), 352; https://doi.org/10.3390/cancers13020352
Available online: https://www.mdpi.com/2072-6694/13/2/352

8. “The Frontal Aslant Tract and Supplementary Motor Area Syndrome: Moving towards a Connectomic Initiation Axis”
by Briggs, R. G.; Allan, P. G.; Poologaindran, A.; Dadario, N. B.; Young, I. M.; Ahsan, S. A.; Teo, C. and Sughrue, M. E.
Cancers 2021, 13(5), 1116; https://doi.org/10.3390/cancers13051116
Available online: https://www.mdpi.com/2072-6694/13/5/1116

9. “Current Intraoperative Imaging Techniques to Improve Surgical Resection of Laryngeal Cancer: A Systematic Review”
by Lauwerends, L. J.; Galema, H. A.; Hardillo, J. A. U.; Sewnaik, A.; Monserez, D.; van Driel, P. B. A. A.; Verhoef, C.; Baatenburg de Jong, R. J.; Hilling, D. E. and Keereweer, S.
Cancers 2021, 13(8), 1895; https://doi.org/10.3390/cancers13081895
Available online: https://www.mdpi.com/2072-6694/13/8/1895

10. “CT Body Composition of Sarcopenia and Sarcopenic Obesity: Predictors of Postoperative Complications and Survival in Patients with Locally Advanced Esophageal Adenocarcinoma”
by Fehrenbach, U.; Wuensch, T.; Gabriel, P.; Segger, L.; Yamaguchi, T.; Auer, T. A.; Beetz, N. L.; Denecke, C.; Kröll, D.; Raakow, J.; Knitter, S.; Chopra, S.; Thuss-Patience, P.; Pratschke, J.; Hamm, B.; Biebl, M. and Geisel, D.
Cancers 2021, 13(12), 2921; https://doi.org/10.3390/cancers13122921
Available online: https://www.mdpi.com/2072-6694/13/12/2921

1. “Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy”
by Aboelella, N. S.; Brandle, C.; Kim, T.; Ding, Z.-C. and Zhou, G.
Cancers 2021, 13(5), 986; https://doi.org/10.3390/cancers13050986
Available online: https://www.mdpi.com/2072-6694/13/5/986

2. “The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression”
by García-Ortiz, A.; Rodríguez-García, Y.; Encinas, J.; Maroto-Martín, E.; Castellano, E.; Teixidó, J. and Martínez-López, J.
Cancers 2021, 13(2), 217; https://doi.org/10.3390/cancers13020217
Available online: https://www.mdpi.com/2072-6694/13/2/217

3. “The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer”
by Ribatti, D.; Solimando, A. G. and Pezzella, F.
Cancers 2021, 13(14), 3433; https://doi.org/10.3390/cancers13143433
Available online: https://www.mdpi.com/2072-6694/13/14/3433

4. “The Role of Hypoxia in Glioblastoma Radiotherapy Resistance”
by Chédeville, A. L. and Madureira, P. A.
Cancers 2021, 13(3), 542; https://doi.org/10.3390/cancers13030542
Available online: https://www.mdpi.com/2072-6694/13/3/542

5. “Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis”
by Datta, A.; Deng, S.; Gopal, V.; Yap, K. C.-H.; Halim, C. E.; Lye, M. L.; Ong, M. S.; Tan, T. Z.; Sethi, G.; Hooi, S. C.; Kumar, A. P. and Yap, C. T.
Cancers 2021, 13(8), 1882; https://doi.org/10.3390/cancers13081882
Available online: https://www.mdpi.com/2072-6694/13/8/1882

6. “Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma”
by Hanamura, I.
Cancers 2021, 13(2), 256; https://doi.org/10.3390/cancers13020256
Available online: https://www.mdpi.com/2072-6694/13/2/256

7. “Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy”
by Bharadwaj, A. G.; Holloway, R. W.; Miller, V. A. and Waisman, D. M.
Cancers 2021, 13(8), 1838; https://doi.org/10.3390/cancers13081838
Available online: https://www.mdpi.com/2072-6694/13/8/1838

8. “Collagen Type XI Alpha 1 (COL11A1): A Novel Biomarker and a Key Player in Cancer”
by Nallanthighal, S.; Heiserman, J. P. and Cheon, D.-J.
Cancers 2021, 13(5), 935; https://doi.org/10.3390/cancers13050935
Available online: https://www.mdpi.com/2072-6694/13/5/935

9. “Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers”
by Ham, I.-H.; Lee, D. and Hur, H.
Cancers 2021, 13(5), 1172; https://doi.org/10.3390/cancers13051172
Available online: https://www.mdpi.com/2072-6694/13/5/1172

10. “Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer”
by Zahra, F. T.; Sajib, M. S. and Mikelis, C. M.
Cancers 2021, 13(6), 1422; https://doi.org/10.3390/cancers13061422
Available online: https://www.mdpi.com/2072-6694/13/6/1422

1. “PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols”
by Crosta, S.; Boldorini, R.; Bono, F.; Brambilla, V.; Dainese, E.; Fusco, N.; Gianatti, A.; L’Imperio, V.; Morbini, P. and Pagni, F.
Cancers 2021, 13(2), 292; https://doi.org/10.3390/cancers13020292
Available online: https://www.mdpi.com/2072-6694/13/2/292

2. “Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology”
by Becker, A. P.; Sells, B. E.; Haque, S. J. and Chakravarti, A.
Cancers 2021, 13(4), 761; https://doi.org/10.3390/cancers13040761
Available online: https://www.mdpi.com/2072-6694/13/4/761

3. “Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases”
by Hu, Z.; Pan, Z.; Chen, W.; Shi, Y.; Wang, W.; Yuan, J.; Wang, E.; Zhang, S.; Kurt, H.; Mai, B.; Zhang, X.; Liu, H.; Rios, A. A.; Ma, H. Y.; Nguyen, N. D.; Medeiros, L. J. and Hu, S.
Cancers 2021, 13(4), 878; https://doi.org/10.3390/cancers13040878
Available online: https://www.mdpi.com/2072-6694/13/4/878

4. “Long, Noncoding RNA Dysregulation in Glioblastoma”
by DeSouza, P. A.; Qu, X.; Chen, H.; Patel, B.; Maher, C. A. and Kim, A. H.
Cancers 2021, 13(7), 1604; https://doi.org/10.3390/cancers13071604
Available online: https://www.mdpi.com/2072-6694/13/7/1604

5. “Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response”
by Rickard, B. P.; Conrad, C.; Sorrin, A. J.; Ruhi, M. K.; Reader, J. C.; Huang, S. A.; Franco, W.; Scarcelli, G.; Polacheck, W. J.; Roque, D. M.; del Carmen, M. G.; Huang, H.-C.; Demirci, U. and Rizvi, I.
Cancers 2021, 13(17), 4318; https://doi.org/10.3390/cancers13174318
Available online: https://www.mdpi.com/2072-6694/13/17/4318

6. “RalGPS2 Interacts with Akt and PDK1 Promoting Tunneling Nanotubes Formation in Bladder Cancer and Kidney Cells Microenvironment”
by D’Aloia, A.; Arrigoni, E.; Costa, B.; Berruti, G.; Martegani, E.; Sacco, E. and Ceriani, M.
Cancers 2021, 13(24), 6330; https://doi.org/10.3390/cancers13246330
Available online: https://www.mdpi.com/2072-6694/13/24/6330

7. “Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors”
by Singh, R.; Fazal, Z.; Freemantle, S. J. and Spinella, M. J.
Cancers 2021, 13(7), 1506; https://doi.org/10.3390/cancers13071506
Available online: https://www.mdpi.com/2072-6694/13/7/1506

8. “Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer”
by Muoio, M. G.; Talia, M.; Lappano, R.; Sims, A. H.; Vella, V.; Cirillo, F.; Manzella, L.; Giuliano, M.; Maggiolini, M.; Belfiore, A. and De Francesco, E. M.
Cancers 2021, 13(4), 621; https://doi.org/10.3390/cancers13040621
Available online: https://www.mdpi.com/2072-6694/13/4/621

9. “Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma”
by Peiseler, M. and Tacke, F.
Cancers 2021, 13(4), 730; https://doi.org/10.3390/cancers13040730
Available online: https://www.mdpi.com/2072-6694/13/4/730

10. “Radio-Iodide Treatment: From Molecular Aspects to the Clinical View”
by De la Vieja, A. and Riesco-Eizaguirre, G.
Cancers 2021, 13(5), 995; https://doi.org/10.3390/cancers13050995
Available online: https://www.mdpi.com/2072-6694/13/5/995

1. “Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer”
by Lopez-Beltran, A.; Cimadamore, A.; Blanca, A.; Massari, F.; Vau, N.; Scarpelli, M.; Cheng, L. and Montironi, R.
Cancers 2021, 13(1), 131; https://doi.org/10.3390/cancers13010131
Available online: https://www.mdpi.com/2072-6694/13/1/131

2. “IL-12 Family Cytokines in Cancer and Immunotherapy”
by Mirlekar, B. and Pylayeva-Gupta, Y.
Cancers 2021, 13(2), 167; https://doi.org/10.3390/cancers13020167
Available online: https://www.mdpi.com/2072-6694/13/2/167

3. “STING Agonists as Cancer Therapeutics”
by Amouzegar, A.; Chelvanambi, M.; Filderman, J. N.; Storkus, W. J. and Luke, J. J.
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
Available online: https://www.mdpi.com/2072-6694/13/11/2695

4. “Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma”
by Ferrucci, P. F.; Pala, L.; Conforti, F. and Cocorocchio, E.
Cancers 2021, 13(6), 1383; https://doi.org/10.3390/cancers13061383
Available online: https://www.mdpi.com/2072-6694/13/6/1383

5. “Senolytics for Cancer Therapy: Is All that Glitters Really Gold?”
by Carpenter, V. J.; Saleh, T. and Gewirtz, D. A.
Cancers 2021, 13(4), 723; https://doi.org/10.3390/cancers13040723
Available online: https://www.mdpi.com/2072-6694/13/4/723

6. “CTLA-4 in Regulatory T Cells for Cancer Immunotherapy”
by Sobhani, N.; Tardiel-Cyril, D. R.; Davtyan, A.; Generali, D.; Roudi, R. and Li, Y.
Cancers 2021, 13(6), 1440; https://doi.org/10.3390/cancers13061440
Available online: https://www.mdpi.com/2072-6694/13/6/1440

7. “The Role of Macrophages in Cancer Development and Therapy”
by Cendrowicz, E.; Sas, Z.; Bremer, E. and Rygiel, T. P.
Cancers 2021, 13(8), 1946; https://doi.org/10.3390/cancers13081946
Available online: https://www.mdpi.com/2072-6694/13/8/1946

8. “The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment”
by Haist, M.; Stege, H.; Grabbe, S.; Bros, M.
Cancers 2021, 13(2), 210; https://doi.org/10.3390/cancers13020210
Available online: https://www.mdpi.com/2072-6694/13/2/210

9. “Immune Resistance in Lung Adenocarcinoma”
by Spella, M. and Stathopoulos, G. T.
Cancers 2021, 13(3), 384; https://doi.org/10.3390/cancers13030384
Available online: https://www.mdpi.com/2072-6694/13/3/384

10. “Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases”
by Bailly, C.; Thuru, X. and Quesnel, B.
Cancers 2021, 13(12), 3034; https://doi.org/10.3390/cancers13123034
Available online: https://www.mdpi.com/2072-6694/13/12/3034

Conference: 2022 BMES Annual Meeting
Date: 12–15 October 2022
Place: San Antonio, Texas, USA
Booth: #346

MDPI will be attending the 2022 BMES Annual Meeting as an exhibitor from 12 to 15 October 2022 in San Antonio, Texas, USA.

BMES holds an annual meeting where they have hosted up to 5,500 biomedical engineers who attend more than 2,500 scientific presentations on cancer treatment, heart disease, women’s health, global health disparities, and more. The meeting allows members to advocate for their innovative solutions, demonstrating their commitment to the society’s core value of health equity for all individuals. In addition, BMES shares scientific information to inspire the up-and-coming generation through four scientific journals, three special interest groups, and collaborations with other scientific societies to elevate the visibility and significant impact that the biomedical engineering community has worldwide as the thought leaders behind the future of human health.

From 12 to 15 October 2022, in the vibrant multicultural city of San Antonio, we will celebrate the tremendous contributions made by BMES members in research, teaching, education, and the workforce that directly impact many sectors of our society. We also aim to highlight equity issues in healthcare and education, stemming from racial and socioeconomic diversity, gender and sexual orientation, and disabilities.

The following MDPI journals will be represented:

• Applied Sciences;
• Bioengineering;
• Biomedicines;
• Biomimetics;
• Biomolecules;
• Biosensors;
• Cancers;
• CIMB;
• Diseases.

Please do not hesitate to reach out if you plan on attending this conference. Our delegates look forward to meeting you in person and answering any questions that you might have.

Peer Review Week began 19 September 2022 under the theme of “Research Integrity: Creating and Supporting Trust in Research”. Through various blog articles, podcast, and webinar, we discussed this crucial subject throughout the week, celebrating the essential role peer review plays in maintaining research quality.

To begin, we held a Webinar on the topic. Professor Peter W. Choate and Dr. Emmanuel Obeng-Gyasi joined Dr. Ioana Craciun, one of MDPI’s scientific officers, for an in-depth discussion.

We invite you to view the event recording:

During the week, the MDPI Blog in a series articles highlighted how good Peer Review safeguards research integrity. The following topics were covered:

• Peer Review Week 2022
• Research Integrity
• What We’ve Learned About Peer Review Reports
• 4 Steps to the Perfect Peer Review Report
• How to Write the Perfect Peer Review Report: An Interview
• Inviting Great Peer Reviewers

In a new edition of Insight Faster, an MDPI podcast, we were delighted to talk to the co-chairs of the Peer Review Week committee, Jayashree Rajagopalan (Senior Manager of Global Community Engagement for CACTUS) and Danielle Padula (Head of Marketing and Community Development at Scholastica) to get their take on this year’s event and its related topics.

You can find the Podcast here.

We hope you enjoy the contents!

1. “Magnetic Nanoparticles—A Multifunctional Potential Agent for Diagnosis and Therapy”
by Chouhan, R. S.; Horvat, M.; Ahmed, J.; Alhokbany, N.; Alshehri, S. M. and Gandhi, S.
Cancers 2021, 13(9), 2213; https://doi.org/10.3390/cancers13092213
Available online: https://www.mdpi.com/2072-6694/13/9/2213 

2. “A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy”
by Andleeb, A.; Andleeb, A.; Asghar, S.; Zaman, G.; Tariq, M.; Mehmood, A.; Nadeem, M.; Hano, C.; Lorenzo, J. M. and Abbasi, B. H.
Cancers 2021, 13(11), 2818; https://doi.org/10.3390/cancers13112818
Available online: https://www.mdpi.com/2072-6694/13/11/2818

3. “Quercetin and Its Nano-Scale Delivery Systems in Prostate Cancer Therapy: Paving the Way for Cancer Elimination and Reversing Chemoresistance”
by Hussain, Y.; Mirzaei, S.; Ashrafizadeh, M.; Zarrabi, A.; Hushmandi, K.; Khan, H. and Daglia, M.
Cancers 2021, 13(7), 1602; https://doi.org/10.3390/cancers13071602
Available online: https://www.mdpi.com/2072-6694/13/7/1602

4. “Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Deep Learning: A Multi-Center and Prospective Validation Study”
by Wei, J.; Jiang, H.; Zeng, M.; Wang, M.; Niu, M.; Gu, D.; Chong, H.; Zhang, Y.; Fu, F.; Zhou, M. et al.
Cancers 2021, 13(10), 2368; https://doi.org/10.3390/cancers13102368
Available online: https://www.mdpi.com/2072-6694/13/10/2368

5. “Radiogenomics: Hunting Down Liver Metastasis in Colorectal Cancer Patients”
by de la Pinta, C.; Castillo, M. E.; Collado, M.; Galindo-Pumariño, C. and Peña, C.
Cancers 2021, 13(21), 5547; https://doi.org/10.3390/cancers13215547
Available online: https://www.mdpi.com/2072-6694/13/21/5547

6. “Breast Tumor Characterization Using [¹⁸F]FDG-PET/CT Imaging Combined with Data Preprocessing and Radiomics”
by Krajnc, D.; Papp, L.; Nakuz, T. S.; Magometschnigg, H. F.; Grahovac, M.; Spielvogel, C. P.; Ecsedi, B.; Bago-Horvath, Z.; Haug, A.; Karanikas, G. et al.
Cancers 2021, 13(6), 1249; https://doi.org/10.3390/cancers13061249
Available online: https://www.mdpi.com/2072-6694/13/6/1249

7. “Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing”
by Francis, J. H.; Richards, A. L.; Mandelker, D. L.; Berger, M. F.; Walsh, M. F.; Dunkel, I. J.; Donoghue, M. T. A. and Abramson, D. H.
Cancers 2021, 13(1), 149; https://doi.org/10.3390/cancers13010149
Available online: https://www.mdpi.com/2072-6694/13/1/149

8. “Use of PET Imaging in Neuro-Oncological Surgery”
by Holzgreve, A.; Albert, N. L.; Galldiks, N. and Suchorska, B.
Cancers 2021, 13(9), 2093; https://doi.org/10.3390/cancers13092093
Available online: https://www.mdpi.com/2072-6694/13/9/2093

9. “Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies”
by Randrian, V.; Evrard, C. and Tougeron, D.
Cancers 2021, 13(12), 3063; https://doi.org/10.3390/cancers13123063
Available online: https://www.mdpi.com/2072-6694/13/12/3063

10. “Validation of a Point-of-Care Optical Coherence Tomography Device with Machine Learning Algorithm for Detection of Oral Potentially Malignant and Malignant Lesions”
by James, B. L.; Sunny, S. P.; Heidari, A. E.; Ramanjinappa, R. D.; Lam, T.; Tran, A. V.; Kankanala, S.; Sil, S.; Tiwari, V.; Patrick, S. et al.
Cancers 2021, 13(14), 3583; https://doi.org/10.3390/cancers13143583
Available online: https://www.mdpi.com/2072-6694/13/14/3583

1. “Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives”
by Hafezi, S. and Rahmani, M.
Cancers 2021, 13(6), 1292; https://doi.org/10.3390/cancers13061292
Available online: https://www.mdpi.com/2072-6694/13/6/1292

2. “Stimuli-Responsive Hydrogels for Cancer Treatment: The Role of pH, Light, Ionic Strength and Magnetic Field”
by Andrade, F.; Roca-Melendres, M. M.; Durán-Lara, E. F.; Rafael, D. and Schwartz, S., Jr.
Cancers 2021, 13(5), 1164; https://doi.org/10.3390/cancers13051164
Available online: https://www.mdpi.com/2072-6694/13/5/1164

3. “The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review”
by Rascio, F.; Spadaccino, F.; Rocchetti, M. T.; Castellano, G.; Stallone, G.; Netti, G. S. and Ranieri, E.
Cancers 2021, 13(16), 3949; https://doi.org/10.3390/cancers13163949
Available online: https://www.mdpi.com/2072-6694/13/16/3949

4. “Perspectives on the Role of Isoliquiritigenin in Cancer”
by Wang, K.-L.; Yu, Y.-C. and Hsia, S.-M.
Cancers 2021, 13(1), 115; https://doi.org/10.3390/cancers13010115
Available online: https://www.mdpi.com/2072-6694/13/1/115

5. “The Role of p53 Signaling in Colorectal Cancer”
by Liebl, M. C. and Hofmann, T. G.
Cancers 2021, 13(9), 2125; https://doi.org/10.3390/cancers13092125
Available online: https://www.mdpi.com/2072-6694/13/9/2125

6. “MicroRNA Therapeutics in Cancer: Current Advances and Challenges”
by Reda El Sayed, S.; Cristante, J.; Guyon, L.; Denis, J.; Chabre, O. and Cherradi, N.
Cancers 2021, 13(11), 2680; https://doi.org/10.3390/cancers13112680
Available online: https://www.mdpi.com/2072-6694/13/11/2680

7. “Glucose Transporters as a Target for Anticancer Therapy”
by Pliszka, M. and Szablewski, L.
Cancers 2021, 13(16), 4184; https://doi.org/10.3390/cancers13164184
Available online: https://www.mdpi.com/2072-6694/13/16/4184

8. “The Exciting New Field of HER2-Low Breast Cancer Treatment”
by Eiger, D.; Agostinetto, E.; Saúde-Conde, R. and de Azambuja, E.
Cancers 2021, 13(5), 1015; https://doi.org/10.3390/cancers13051015
Available online: https://www.mdpi.com/2072-6694/13/5/1015

9. “Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy”
by Kato, T.; Wakiyama, H.; Furusawa, A.; Choyke, P. L. and Kobayashi, H.
Cancers 2021, 13(11), 2535; https://doi.org/10.3390/cancers13112535
Available online: https://www.mdpi.com/2072-6694/13/11/2535

10. “Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours”
by Setargew, Y. F. I.; Wyllie, K.; Grant, R. D.; Chitty, J. L. and Cox, T. R.
Cancers 2021, 13(3), 491; https://doi.org/10.3390/cancers13030491
Available online: https://www.mdpi.com/2072-6694/13/3/491

MDPI will be attending the 34th Annual Conference of the International Society for Environmental Epidemiology (ISEE 2022), held in Athens, Greece, from 18 to 21 September 2022. The main theme of the 2022 conference is “Strengthening the global role of environmental epidemiology”, stressing the need to study and understand local conditions in order to synthesize knowledge and make a difference for our planet. In the 2022 conference we will continue advancing our society’s aims in promoting epidemiological studies that link environmental exposures to human health.

During this conference, MDPI (at booth #22) will welcome researchers from different backgrounds to visit and share their latest inspirations with us.

The following MDPI journals will be represented:

• IJERPH (leading journal);
• Sustainability;
• Healthcare;
• Children;
• Cancers;
• Climate;
• Environments;
• Earth;
• Societies;
• Epidemiologia.

If you plan on attending this conference, feel free to stop by our booth: #22. Our delegates look forward to meeting you in person to answer any questions that you may have.

For more information about the conference, please see the following link: https://isee2022.org/.

1 . “Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany”
by Jacob, L.; Loosen, S. H.; Kalder, M.; Luedde, T.; Roderburg, C.; Kostev, K.
Cancers 2021, 13(3), 408; https://doi.org/10.3390/cancers13030408
Available online: https://www.mdpi.com/2072-6694/13/3/408

2. “A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer”
by Yasin, H. K.; Taylor, A. H.; Ayakannu, T.
Cancers 2021, 13(9), 2149; https://doi.org/10.3390/cancers13092149
Available online: https://www.mdpi.com/2072-6694/13/9/2149

3. “Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies”
by Lorini, L.; Bescós Atín, C.; Thavaraj, S.; Müller-Richter, U.; Alberola Ferranti, M.; Pamias Romero, J.; Sáez Barba, M.; de Pablo García-Cuenca, A.; Braña García, I.; Bossi, P. et al.
Cancers 2021, 13(15), 3696; https://doi.org/10.3390/cancers13153696
Available online: https://www.mdpi.com/2072-6694/13/15/3696

4. “Fucoxanthin and Colorectal Cancer Prevention”
by Terasaki, M.; Kubota, A.; Kojima, H.; Maeda, H.; Miyashita, K.; Kawagoe, C.; Mutoh, M.; Tanaka, T.
Cancers 2021, 13(10), 2379; https://doi.org/10.3390/cancers13102379
Available online: https://www.mdpi.com/2072-6694/13/10/2379

5. “Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study”
by Lee, J.; Park, S.-S.; Kim, T. Y.; Lee, D.-G.; Kim, D.-W.
Cancers 2021, 13(3), 471; https://doi.org/10.3390/cancers13030471
Available online: https://www.mdpi.com/2072-6694/13/3/471

6. “Mycobiome and Cancer: What Is the Evidence?”
by Lee, J.; Park, S.-S.; Kim, T.Y.; Lee, D.-G.; Kim, D.-W.
Cancers 2021, 13(13), 3149; https://doi.org/10.3390/cancers13133149
Available online: https://www.mdpi.com/2072-6694/13/13/3149

7. “Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level”
by Bernard, A.; Cottenet, J.; Bonniaud, P.; Piroth, L.; Arveux, P.; Tubert-Bitter, P.; Quantin, C.
Cancers 2021, 13(6), 1436; https://doi.org/10.3390/cancers13061436
Available online: https://www.mdpi.com/2072-6694/13/6/1436

8. “Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review”
by Ferrari, A.; Neefs, I.; Hoeck, S.; Peeters, M.; Van Hal, G.
Cancers 2021, 13(8), 1820; https://doi.org/10.3390/cancers13081820
Available online: https://www.mdpi.com/2072-6694/13/8/1820

9. “Renal Cell Carcinoma Health Disparities in Stage and Mortality among American Indians/Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry Data”
by Valencia, C. I.; Asmar, S.; Hsu, C.-H.; Gachupin, F. C.; Wong, A. C.; Chipollini, J.; Lee, B. R.; Batai, K.
Cancers 2021, 13(5), 990; https://doi.org/10.3390/cancers13050990
Available online: https://www.mdpi.com/2072-6694/13/5/990

10. “Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients”
by Valencia, C. I.; Asmar, S.; Hsu, C.-H.; Gachupin, F. C.; Wong, A. C.; Chipollini, J.; Lee, B. R.; Batai, K. et al.
Cancers 2021, 13(17), 4312; https://doi.org/10.3390/cancers13174312
Available online: https://www.mdpi.com/2072-6694/13/17/4312

1. “The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia”
by Lühmann, J. L.; Stelter, M.; Wolter, M.; Kater, J.; Lentes, J.; Bergmann, A. K.; Schieck, M.; Göhring, G.; Möricke, A.; Cario, G. et al.
Cancers 2021, 13(17), 4388; https://doi.org/10.3390/cancers13174388
Available online: https://www.mdpi.com/2072-6694/13/17/4388

2. “The Microbiome in Childhood Acute Lymphoblastic Leukemia”
by Oldenburg, M.; Rüchel, N.; Janssen, S.; Borkhardt, A.; Gössling, K. L.
Cancers 2021, 13(19), 4947; https://doi.org/10.3390/cancers13194947
Available online: https://www.mdpi.com/2072-6694/13/19/4947

3. “Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT)”
by Gautier, M.; Thirant, C.; Delattre, O.; Janoueix-Lerosey, I.
Cancers 2021, 13(12), 2904; https://doi.org/10.3390/cancers13122904
Available online: https://www.mdpi.com/2072-6694/13/12/2904
 
4. “Pediatric Mixed-Phenotype Acute Leukemia: What’s New?”
by Batra, S.; Ross, A. J.
Cancers 2021, 13(18), 4658; https://doi.org/10.3390/cancers13184658
Available online: https://www.mdpi.com/2072-6694/13/18/4658
 
5. “Preliminary Radiogenomic Evidence for the Prediction of Metastasis and Chemotherapy Response in Pediatric Patients with Osteosarcoma Using 18F-FDG PET/CT, EZRIN, and KI67”
by Kim, B.-C.; Kim, J.; Kim, K.; Byun, B. H.; Lim, I.; Kong, C.-B.; Song, W. S.; Koh, J.-S.; Woo, S.-K.
Cancers 2021, 13(11), 2671; https://doi.org/10.3390/cancers13112671
Available online: https://www.mdpi.com/2072-6694/13/11/2671
 
6. “Unbalance in Iron Metabolism in Childhood Leukemia Converges with Treatment Intensity: Biochemical and Clinical Analysis”
by Łęcka, M.; Słomka, A.; Albrecht, K.; Żekanowska, E.; Romiszewski, M.; Styczyński, J.
Cancers 2021, 13(12), 3029; https://doi.org/10.3390/cancers13123029
Available online: https://www.mdpi.com/2072-6694/13/12/3029
 
7. “Natural History of Untreated Retinoblastoma”
by Zhao, J.; Feng, Z.; Gallie, B. L.
Cancers 2021, 13(15), 3646; https://doi.org/10.3390/cancers13153646
Available online: https://www.mdpi.com/2072-6694/13/15/3646
 
8. “Advances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019”
by Czogała, M.; Balwierz, W.; Pawińska-Wąsikowska, K.; Książek, T.; Bukowska-Strakova, K.; Czogała, W.; Sikorska-Fic, B.; Matysiak, M.; Skalska-Sadowska, J.; Wachowiak, J. et al.
Cancers 2021, 13(18), 4536; https://doi.org/10.3390/cancers13184536
Available online: https://www.mdpi.com/2072-6694/13/18/4536
 
9. “Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics”
by Chouvarine, P.; Antić, Ž.; Lentes, J.; Schröder, C.; Alten, J.; Brüggemann, M.; Carrillo-de Santa Pau, E.; Illig, T.; Laguna, T.; Schewe, D. et al.
Cancers 2021, 13(22), 5653; https://doi.org/10.3390/cancers13225653
Available online: https://www.mdpi.com/2072-6694/13/22/5653
 
10. “Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma”
by Nasarre, P.; Garcia, D. I.; Siegel, J. B.; Bonilla, I. V.; Mukherjee, R.; Hilliard, E.; Chakraborty, P.; Nasarre, C.; Yustein, J. T.; Lang, M. et al.
Cancers 2021, 13(11), 2696; https://doi.org/10.3390/cancers13112696
Available online: https://www.mdpi.com/2072-6694/13/11/2696

MDPI will be attending the 2022 CAGPO ACMOO Annual Conference, hosted by the 2022 CAGPO Annual Conference Committee, which will be held from 15 to 18 September 2022 in Toronto, Canada.

The CAGPO mission statement is to unify general practitioners in oncology, promote communication amongst general practitioners in oncology in tertiary care and primary care settings, act and speak as the recognized authority on behalf of and for the benefit of general practitioners in oncology and their interests, and promote the role of general practitioners in oncology within cancer centers and within the primary care setting. The conference is to address the learning needs of general practitioners in oncology (GPOs) and oncology-allied health attendees. During this meeting, we will address recent advancements in the standards of oncology care. Our speakers include GPOs, medical and radiation oncologists, as well as speakers from the disciplines of family medicine and clinical trials.

The following MDPI journals will be represented:

• Current Oncology (leading);
• Cancers;
• Medical Sciences;
• Pharmacy;
• Journal of Clinical Medicine;
• Cells;
• Onco.

If you are attending this conference, please feel free to start an on-site conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have.

For more information about the conference, please visit the following link: http://cagpo-annual-conference.ca, or contact the Current Oncology Editorial Office at curroncol@mdpi.com.

MDPI will be attending ASHG 2022, held in Los Angeles, USA, from 25 to 29 October 2022.

The following MDPI journals will be represented:

• Genes;
• JPM;
• Biomedicines;
• Biomolecules;
• Cardiogenetics;
• Cancers;
• Brain Science;
• Symmetry;
• Diagnostics;
• Metabolites;
• Cells;
• Biology;
• Humans;
• DNA.

If you plan on attending this conference, feel free to stop by our booth: #1844. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please see the following link:

https://www.ashg.org/meetings/2022-annual-meeting/.

1. “Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries”
by Huang, J.; Koulaouzidis, A.; Marlicz, W.; Lok, V.; Chu, C.; Ngai, C. H.; Zhang, L.; Chen, P.; Wang, S.; Yuan, J.; et al.
Cancers 2021, 13(1), 141; https://doi.org/10.3390/cancers13010141
Available online: https://www.mdpi.com/2072-6694/13/1/141

2. “A Review of Circulating Tumour Cell Enrichment Technologies”
by Rushton, A. J.; Nteliopoulos, G.; Shaw, J. A.; Coombes, R. C.
Cancers 2021, 13(5), 970; https://doi.org/10.3390/cancers13050970
Available online: https://www.mdpi.com/2072-6694/13/5/970

3. “Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy”
by Koustoulidou, S.; Hoorens, M. W. H.; Dalm, S. U.; Mahajan, S.; Debets, R.; Seimbille, Y.; de Jong, M.
Cancers 2021, 13(5), 1100; https://doi.org/10.3390/cancers13051100
Available online: https://www.mdpi.com/2072-6694/13/5/1100

4. “Home-Based Aerobic and Resistance Exercise Interventions in Cancer Patients and Survivors: A Systematic Review”
by Batalik, L.; Winnige, P.; Dosbaba, F.; Vlazna, D.; Janikova, A.
Cancers 2021, 13(8), 1915; https://doi.org/10.3390/cancers13081915
Available online: https://www.mdpi.com/2072-6694/13/8/1915

5. “Exploring the Potential Role of the Gut Microbiome in Chemotherapy-Induced Neurocognitive Disorders and Cardiovascular Toxicity”
by Ciernikova, S.; Mego, M.; Chovanec, M.
Cancers 2021, 13(4), 782; https://doi.org/10.3390/cancers13040782
Available online: https://www.mdpi.com/2072-6694/13/4/782

6. “Fatigue in Cancer Patients in Palliative Care—A Review on Pharmacological Interventions”
by Klasson, C.; Helde Frankling, M.; Lundh Hagelin, C.; Björkhem-Bergman, L.
Cancers 2021, 13(5), 985; https://doi.org/10.3390/cancers13050985
Available online: https://www.mdpi.com/2072-6694/13/5/985

7. “Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data”
by Hansen, T. F.; Qvortrup, C.; Pfeiffer, P.
Cancers 2021, 13(5), 1031; https://doi.org/10.3390/cancers13051031
Available online: https://www.mdpi.com/2072-6694/13/5/1031

8. “Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview”
by Janssen, S. H. M.; van der Graaf, W. T. A.; van der Meer, D. J.; Manten-Horst, E.; Husson, O.
Cancers 2021, 13(19), 4847; https://doi.org/10.3390/cancers13194847
Available online: https://www.mdpi.com/2072-6694/13/19/4847

9. “Comparative Evaluation of Novel ¹⁷⁷Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting”
by Tano, H.; Oroujeni, M.; Vorobyeva, A.; Westerlund, K.; Liu, Y.; Xu, T.; Vasconcelos, D.; Orlova, A.; Karlström, A. E.; Tolmachev, V.
Cancers 2021, 13(3), 500; https://doi.org/10.3390/cancers13030500
Available online: https://www.mdpi.com/2072-6694/13/3/500

10. “Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy”
by Li, Y.; Lustberg, M. B.; Hu, S.
Cancers 2021, 13(4), 766; https://doi.org/10.3390/cancers13040766
Available online: https://www.mdpi.com/2072-6694/13/4/766

1. “Trends in Research on Exosomes in Cancer Progression and Anticancer Therapy”
by Sinha, D.; Roy, S.; Saha, P.; Chatterjee, N.; Bishayee, A.
Cancers 2021, 13(2), 326; https://doi.org/10.3390/cancers13020326
Available online: https://www.mdpi.com/2072-6694/13/2/326

2. “Mechanisms of Resistance to KRASG12C Inhibitors”
by Dunnett-Kane, V.; Nicola, P.; Blackhall, F.; Lindsay, C.
Cancers 2021, 13(1), 151; https://doi.org/10.3390/cancers13010151
Available online: https://www.mdpi.com/2072-6694/13/1/151

3. “Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter”
by Hompland, T.; Fjeldbo, C. S.; Lyng, H.
Cancers 2021, 13(3), 499; https://doi.org/10.3390/cancers13030499
Available online: https://www.mdpi.com/2072-6694/13/3/499

4. “Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression”
by Papatsirou, M.; Artemaki, P. I.; Karousi, P.; Scorilas, A.; Kontos, C. K.
Cancers 2021, 13(11), 2744; https://doi.org/10.3390/cancers13112744
Available online: https://www.mdpi.com/2072-6694/13/11/2744

5. “Targeting CDK9 for Anti-Cancer Therapeutics”
by Mandal, R.; Becker, S.; Strebhardt, K.
Cancers 2021, 13(9), 2181; https://doi.org/10.3390/cancers13092181
Available online: https://www.mdpi.com/2072-6694/13/9/2181

6. “EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance”
by Uribe, M. L.; Marrocco, I.; Yarden, Y.
Cancers 2021, 13(11), 2748; https://doi.org/10.3390/cancers13112748
Available online: https://www.mdpi.com/2072-6694/13/11/2748

7. “The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma”
by Ou A.; Ott M.; Fang D.; Heimberger A. B.
Cancers 2021, 13(3), 437; https://doi.org/10.3390/cancers13030437
Available online: https://www.mdpi.com/2072-6694/13/3/437

8. “Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer”
by Domen, A.; Quatannens, D.; Zanivan, S.; Deben, C.; Van Audenaerde, J.; Smits, E.; Wouters, A.; Lardon, F.; Roeyen, G.; Verhoeven, Y.; Janssens, A.; Vandamme, T.; van Dam, P.; Peeters, M.; Prenen, H. 
Cancers 2021, 13(5), 987; https://doi.org/10.3390/cancers13050987
Available online: https://www.mdpi.com/2072-6694/13/5/987

9. “Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies”
by Hattinger, C. M.; Patrizio, M. P.; Fantoni, L.; Casotti, C.; Riganti, C.; Serra, M.
Cancers 2021, 13(12), 2878; https://doi.org/10.3390/cancers13122878
Available online: https://www.mdpi.com/2072-6694/13/12/2878

10. “Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing”
by Kabakov, A. E.; Yakimova, A. O. 
Cancers 2021, 13(5), 1102; https://doi.org/10.3390/cancers13051102
Available online: https://www.mdpi.com/2072-6694/13/5/1102

Cancers (ISSN: 2072-6694) will be attending ESMO 2022, held in Paris, France, from 9 to 13 September 2022. The European Society for Medical Oncology (ESMO) conference is the most important annual event with the greatest impact on cancer research, open to scholars and specialists from academia and the medical profession. During this conference, MDPI (at booth #P231) will welcome researchers from different backgrounds to visit and share their latest inspirations with us.

The following MDPI journals will be represented:

• Cancers (leading journal);
• Cells;
• Current Oncology;
• Biomedicines;
• Diagnostics;
• Future Pharmacology;
• IJMS;
• Onco;
• Pharmaceutics.

If you plan on attending this conference, feel free to stop by our booth #P231. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please see the following link: https://www.esmo.org/.

1. “Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study”
by Banys-Paluchowski, M.; Gasparri, M. L.; de Boniface, J.; Gentilini, O.; Stickeler, E.; Hartmann, S.; Thill, M.; Rubio, I. T.; Di Micco, R.; Bonci, E.-A.; et al.
Cancers 2021, 13(7), 1565; https://doi.org/10.3390/Cancers13071565
Available online: https://www.mdpi.com/2072-6694/13/7/1565 

2. “Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials”
by Rochigneux, P.; Chanez, B.; De Rauglaudre, B.; Mitry, E.; Chabannon, C.; Gilabert, M.
Cancers 2021, 13(2), 271; https://doi.org/10.3390/Cancers13020271
Available online: https://www.mdpi.com/2072-6694/13/2/271

3. “Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations”
by Lee, P. C.; Hendifar, A.; Osipov, A.; Cho, M.; Li, D.; Gong, J.
Cancers 2021, 13(7), 1706; https://doi.org/10.3390/Cancers13071706
Available online: https://www.mdpi.com/2072-6694/13/7/1706

4. “The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials”
by Hervieu, C.; Christou, N.; Battu, S.; Mathonnet, M.
Cancers 2021, 13(5), 1092; https://doi.org/10.3390/Cancers13051092
Available online: https://www.mdpi.com/2072-6694/13/5/1092

5. “N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence”
by Newell, M.; Mazurak, V.; Postovit, L. M.; Field, C. J.
Cancers 2021, 13(6), 1206; https://doi.org/10.3390/Cancers13061206
Available online: https://www.mdpi.com/2072-6694/13/6/1206

6. “Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance”
by Wang, S.-H.; Yeh, S.-H.; Chen, P.-J.
Cancers 2021, 13(10), 2454; https://doi.org/10.3390/Cancers13102454
Available online: https://www.mdpi.com/2072-6694/13/10/2454

7. “The Effects of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Inflammatory Markers, Body Composition, and Physical Fitness in Overweight/Obese Survivors of Breast Cancer: A Randomized Controlled Clinical Trial”
by Hooshmand Moghadam, B.; Golestani, F.; Bagheri, R.; Cheraghloo, N.; Eskandari, M.; Wong, A.; Nordvall, M.; Suzuki, K.; Pournemati, P.
Cancers 2021, 13(17), 4386; https://doi.org/10.3390/Cancers13174386
Available online: https://www.mdpi.com/2072-6694/13/17/4386

8. “Interstitial Photodynamic Therapy for Glioblastomas: A Standardized Procedure for Clinical Use”
by Leroy, H.-A.; Baert, G.; Guerin, L.; Delhem, N.; Mordon, S.; Reyns, N.
Cancers 2021, 13(22), 5754; https://doi.org/10.3390/Cancers13225754
Available online: https://www.mdpi.com/2072-6694/13/22/5754

9. “Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications”
by van Harten, A. M.; Brakenhoff, R. H.
Cancers 2021, 13(11), 2774; https://doi.org/10.3390/Cancers13112774
Available online: https://www.mdpi.com/2072-6694/13/11/2774

10. “Could Photodynamic Therapy Be a Promising Therapeutic Modality in Hepatocellular Carcinoma Patients? A Critical Review of Experimental and Clinical Studies”
by Kumar, A.; Moralès, O.; Mordon, S.; Delhem, N.
Cancers 2021, 13(20), 5176; https://doi.org/10.3390/Cancers13205176
Available online: https://www.mdpi.com/2072-6694/13/20/5176

1. “Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?”
by Victoria Heredia-Soto; Nuria Rodríguez-Salas; Jaime Feliu
Cancers 2021, 13(8), 1986; https://doi.org/10.3390/cancers13081986
Available online: https://www.mdpi.com/2072-6694/13/8/1986

2. “New Molecular Mechanisms and Clinical Impact of circRNAs in Human Cancer”
by Giulia Fontemaggi; Chiara Turco; Gabriella Esposito; Silvia Di Agostino
Cancers 2021, 13(13), 3154; https://doi.org/10.3390/cancers13133154
Available online: https://www.mdpi.com/2072-6694/13/13/3154

3. “Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer”
by Matthew G. Davey; Sean O. Hynes; Michael J. Kerin; Nicola Miller; Aoife J. Lowery
Cancers 2021, 13(17), 4455; https://doi.org/10.3390/cancers13174455
Available online: https://www.mdpi.com/2072-6694/13/17/4455

4. “Functional Interaction among lncRNA HOTAIR and MicroRNAs in Cancer and Other Human Diseases”
by Monica Cantile; Maurizio Di Bonito; Maura Tracey De Bellis; Gerardo Botti
Cancers 2021, 13(3), 570; https://doi.org/10.3390/cancers13030570
Available online: https://www.mdpi.com/2072-6694/13/3/570

5. “Resistance to Molecularly Targeted Therapies in Melanoma”
by Meet Patel; Adam Eckburg; Shahina Gantiwala; Zachary Hart; Joshua Dein; Katie Lam; Neelu Puri
Cancers 2021, 13(5), 1115; https://doi.org/10.3390/cancers13051115
Available online: https://www.mdpi.com/2072-6694/13/5/1115

6. “Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease”
by Gian Paolo Caviglia; Angelo Armandi; Chiara Rosso; Silvia Gaia; Serena Aneli; Emanuela Rolle; Maria Lorena Abate; Antonella Olivero; Aurora Nicolosi; Marta Guariglia; Davide Giuseppe Ribaldone; Patrizia Carucci; Giorgio Maria Saracco; Elisabetta Bugianesi
Cancers 2021, 13(10), 2305; https://doi.org/10.3390/cancers13102305
Available online: https://www.mdpi.com/2072-6694/13/10/2305

7. “Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)”
by Pauline Gilson; Jean-Louis Merlin; Alexandre Harlé
Cancers 2021, 13(7), 1491; https://doi.org/10.3390/cancers13071491
Available online: https://www.mdpi.com/2072-6694/13/7/1491

8. “Urine as a Source of Liquid Biopsy for Cancer”
by Masanori Oshi; Vijayashree Murthy; Hideo Takahashi; Michelle Huyser; Maiko Okano; Yoshihisa Tokumaru; Omar M. Rashid; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Cancers 2021, 13(11), 2652; https://doi.org/10.3390/cancers13112652
Available online: https://www.mdpi.com/2072-6694/13/11/2652

9. “Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review”
by Greta Brezgyte; Vinay Shah; Daria Jach; Tatjana Crnogorac-Jurcevic
Cancers 2021, 13(11), 2722; https://doi.org/10.3390/cancers13112722
Available online: https://www.mdpi.com/2072-6694/13/11/2722

10. “Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies”
by Cora Palanca-Ballester; Aitor Rodriguez-Casanova; Susana Torres; Silvia Calabuig-Fariñas; Francisco Exposito; Diego Serrano; Esther Redin; Karmele Valencia; Eloisa Jantus-Lewintre; Angel Diaz-Lagares; Luis Montuenga; Juan Sandoval; Alfonso Calvo
Cancers 2021, 13(12), 3016; https://doi.org/10.3390/cancers13123016
Available online: https://www.mdpi.com/2072-6694/13/12/3016

Vaccines help the body fight disease and therefore immunization is a key component of primary health care and is a development success story that saves millions of lives every year. They work to protect the body from viruses (e.g., human papillomavirus, hepatitis B virus) or boost the body's immune system to fight cancer.

August is National Immunization Awareness Month, and we would like to share some of the high-quality and innovative research findings published in Cancers (ISSN: 2072-6694).

The list of relevant papers can be seen below:

“Plasma-Activated Medium Potentiates the Immunogenicity of Tumor Cell Lysates for Dendritic Cell-Based Cancer Vaccines”
by Tomić, S.; Petrović, A.; Puač, N.; Škoro, N.; Bekić, M.; Petrović, Z. L.; Čolić, M.
Cancers 2021, 13(7), 1626; https://doi.org/10.3390/cancers13071626
Available online: https://www.mdpi.com/2072-6694/13/7/1626

“COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience”
by So, A. C. P.; McGrath, H.; Ting, J.; Srikandarajah, K.; Germanou, S.; Moss, C.; Russell, B.; Monroy-Iglesias, M.; Dolly, S.; Irshad, S.; Van Hemelrijck, M.; Enting, D.
Cancers 2021, 13(14), 3573; https://doi.org/10.3390/cancers13143573
Available online: https://www.mdpi.com/2072-6694/13/14/3573

“Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs”
by Agbarya, A.; Sarel, I.; Ziv-Baran, T.; Agranat, S.; Schwartz, O.; Shai, A.; Nordheimer, S.; Fenig, S.; Shechtman, Y.; Kozlener, E.; Taha, T.; Nasrallah, H.; Parikh, R.; Elkoshi, N.; Levy, C.; Khoury, R.; Brenner, R.
Cancers 2021, 13(16), 4191; https://doi.org/10.3390/cancers13164191
Available online: https://www.mdpi.com/2072-6694/13/16/4191

“Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy”
by Horn, L. A.; Fousek, K.; Hamilton, D. H.; Hodge, J. W.; Zebala, J. A.; Maeda, D. Y.; Schlom, J.; Palena, C.
Cancers 2021, 13(5), 968; https://doi.org/10.3390/cancers13050968
Available online: https://www.mdpi.com/2072-6694/13/5/968

“Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment”
by Ghandili, S.; Schönlein, M.; Lütgehetmann, M.; Schulze zur Wiesch, J.; Becher, H.; Bokemeyer, C.; Sinn, M.; Weisel, K. C.; Leypoldt, L. B.
Cancers 2021, 13(15), 3800; https://doi.org/10.3390/cancers13153800
Available online: https://www.mdpi.com/2072-6694/13/15/3800

“Antigenic Essence: Upgrade of Cellular Cancer Vaccines”
by Lokhov, P. G.; Balashova, E. E.
Cancers 2021, 13(4), 774; https://doi.org/10.3390/cancers13040774
Available online: https://www.mdpi.com/2072-6694/13/4/774

“Vaccine-Based Immunotherapy for Head and Neck Cancers”
by Beyaert, S.; Machiels, J. -P.; Schmitz, S.
Cancers 2021, 13(23), 6041; https://doi.org/10.3390/cancers13236041
Available online: https://www.mdpi.com/2072-6694/13/23/6041

“Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization”
by Przybyla, A.; Lehmann, A. A.; Zhang, T.; Mackiewicz, J.; Galus, Ł.; Kirchenbaum, G. A.; Mackiewicz, A.; Lehmann, P. V.
Cancers 2021, 13(2), 223; https://doi.org/10.3390/cancers13020223
Available online: https://www.mdpi.com/2072-6694/13/2/223

“Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study”
by Jørgensen, N. G.; Kaae, J.; Grauslund, J. H.; Met, Ö.; Nielsen, S. L.; Pedersen, A. W.; Svane, I. M.; Ehrnrooth, E.; Andersen, M. H.; Zachariae, C.; Skov, L.
Cancers 2021, 13(4), 911; https://doi.org/10.3390/cancers13040911
Available online: https://www.mdpi.com/2072-6694/13/4/911

“Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice”
by Belnoue, E.; Leystra, A. A.; Carboni, S.; Cooper, H. S.; Macedo, R. T.; Harvey, K. N.; Colby, K. B.; Campbell, K. S.; Vanderveer, L. A.; Clapper, M. L.; Derouazi, M.
Cancers 2021, 13(4), 845; https://doi.org/10.3390/cancers13040845
Available online: https://www.mdpi.com/2072-6694/13/4/845

You are welcome to submit relevant papers to the journal Section “Cancer Immunology and Immunotherapy” at https://www.mdpi.com/journal/cancers/sections/Cancer_Immunology_Immunotherapy.

Dr. Subbaya Subramanian
Associate Section Editor-in-Chief of Cancers

Sarcomas are malignant tumors that commonly arise from bone and soft tissue such as muscle, fat, and nerves. Bone sarcomas include osteosarcoma, chondrosarcoma, and Ewing’s sarcoma, and soft-tissue sarcomas include liposarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, synovial sarcoma, leiomyosarcoma, and rhabdomyosarcoma. The characteristics of sarcoma are its rarity (low frequency of occurrence) and diversity (various histological types). The frequency of sarcoma is extremely low compared to carcinomas such as lung cancer and colon cancer, and sarcomas account for only 1% of all malignant tumors.

Due to the rarity and variety of sarcoma, it is difficult to diagnose and treat the disease appropriately. In addition, many patients are referred to cancer centers after receiving unplanned excision.

July has been designated as “Sarcoma Awareness Month”, with the yellow ribbon as a symbol, and various activities have been carried out so far to raise awareness of this rare cancer for research support and development in treatment all over the world.

We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to highlight multiple research projects in this field, covering mechanisms in the tumor microenvironment, early detection, promising therapeutic targets, and new therapeutic strategies. We hope this announcement will provide useful information for clinical practice.

The list of relevant papers can be seen below:

• “Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?”
  by Anne Gomez-Brouchet et al.
  Available online: https://www.mdpi.com/2072-6694/13/3/423

• “Exploring Metabolic Adaptations to the Acidic Microenvironment of Osteosarcoma Cells Unveils Sphingosine 1-Phosphate as a Valuable Therapeutic Target”
  by Margherita Cortini et al.
  Available online: https://www.mdpi.com/2072-6694/13/2/311

• “Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies”
  by Claudia Maria Hattinger et al.
  Available online: https://www.mdpi.com/2072-6694/13/12/2878

• “Chondrosarcoma-from Molecular Pathology to Novel Therapies”
  by Agnieszka E. Zając et al.
  Available online: https://www.mdpi.com/2072-6694/13/10/2390

• “Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy”
  by Luana Madalena Sousa et al.
  Available online: https://www.mdpi.com/2072-6694/13/15/3885

You are welcome to submit relevant papers to the Special Issue “Sarcoma and Bone Cancer Awareness Month” at https://www.mdpi.com/si/cancers/IQ9P79398L.

Dr. Shinji Miwa, Editorial Board Member of Cancers

The 2021 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals: